{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/mnt/public3/caogs/anaconda3/envs/deepseek/lib/python3.11/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "os.environ[\"HF_ENDPOINT\"] = \"https://hf-mirror.com\"\n",
    "os.environ[\"CUDA_VISIBLE_DEVICES\"] = \"1\"\n",
    "import torch\n",
    "from transformers import AutoTokenizer, AutoModelForCausalLM\n",
    "import pandas as pd\n",
    "import sys\n",
    "sys.path.insert(0, \"/public/workspace/caoguangshuo/public6/Pancancer/cancerGPT/CellReasoner\")\n",
    "from utils import run_inference, plot_cross_label_heatmap, plot_score_stacked_bar, plot_score_violin"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "reasoning_mode = False\n",
    "eval_file_path = \"/public/workspace/caoguangshuo/public6/Pancancer/cancerGPT/CellReasoner/output/pbmc_demo_for_CellReasoner.json\"\n",
    "data_name = os.path.basename(eval_file_path).split('.')[0].replace('_for_CellReasoner', '')\n",
    "out_path = \"/public/workspace/caoguangshuo/public6/Pancancer/cancerGPT/CellReasoner/output\"\n",
    "has_label = True\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "test_df =  pd.read_json(eval_file_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/mnt/public3/caogs/anaconda3/envs/deepseek/lib/python3.11/site-packages/transformers/generation/configuration_utils.py:818: UserWarning: `return_dict_in_generate` is NOT set to `True`, but `output_hidden_states` is. When `return_dict_in_generate` is not `True`, `output_hidden_states` is ignored.\n",
      "  warnings.warn(\n",
      "Loading checkpoint shards: 100%|██████████| 4/4 [00:10<00:00,  2.64s/it]\n"
     ]
    }
   ],
   "source": [
    "model_name = \"guangshuo/CellReasoner-7B\"\n",
    "model = AutoModelForCausalLM.from_pretrained(\n",
    "    model_name,\n",
    "    device_map=\"auto\",    \n",
    "    output_hidden_states=True,\n",
    "    torch_dtype=torch.bfloat16,\n",
    "    attn_implementation=\"flash_attention_2\", \n",
    "    trust_remote_code=True\n",
    "    )\n",
    "tokenizer = AutoTokenizer.from_pretrained(model_name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processing batch 1/9\n",
      "Processing batch 3/9\n",
      "Processing batch 5/9\n",
      "Processing batch 7/9\n",
      "Processing batch 9/9\n",
      "Inference finished.\n"
     ]
    }
   ],
   "source": [
    "output_data = run_inference(\n",
    "    model=model,\n",
    "    tokenizer=tokenizer,\n",
    "    data=test_df,  # DataFrame with columns: input, instruction, cell_name, (optional) output\n",
    "    batch_size=4, #GTX 4090 recommend 4\n",
    "    log_interval=2,\n",
    "    reasoning_mode=False,\n",
    "    has_label=True\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 900x700 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "output_data_df = pd.DataFrame(output_data)\n",
    "plot_cross_label_heatmap(output_data_df,'labels', 'response', normalize=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "pair_score_path = \"/public/workspace/caoguangshuo/public6/Pancancer/cancerGPT/CellReasoner/data/all_pair_score.xlsx\"\n",
    "pair_score = pd.read_excel(pair_score_path, engine='openpyxl')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "output_data_df = output_data_df.merge(pair_score, how='left', left_on=[\"labels\", \"response\"], right_on=[\"Ground Truth\", \"Model Prediction\"]).drop(columns=[\"Ground Truth\", \"Model Prediction\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/public/workspace/caoguangshuo/public6/Pancancer/cancerGPT/CellReasoner/utils.py:207: FutureWarning: \n",
      "\n",
      "Passing `palette` without assigning `hue` is deprecated and will be removed in v0.14.0. Assign the `x` variable to `hue` and set `legend=False` for the same effect.\n",
      "\n",
      "  ax = sns.violinplot(\n",
      "/public/workspace/caoguangshuo/public6/Pancancer/cancerGPT/CellReasoner/utils.py:207: UserWarning: The palette list has more values (6) than needed (1), which may not be intended.\n",
      "  ax = sns.violinplot(\n",
      "/public/workspace/caoguangshuo/public6/Pancancer/cancerGPT/CellReasoner/utils.py:232: UserWarning: set_ticklabels() should only be used with a fixed number of ticks, i.e. after set_ticks() or using a FixedLocator.\n",
      "  ax.set_xticklabels(new_labels)\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 400x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/public/workspace/caoguangshuo/public6/Pancancer/cancerGPT/CellReasoner/utils.py:397: FutureWarning: Series.__getitem__ treating keys as positions is deprecated. In a future version, integer keys will always be treated as labels (consistent with DataFrame behavior). To access a value by position, use `ser.iloc[pos]`\n",
      "  total_height = bottom[i]\n",
      "/public/workspace/caoguangshuo/public6/Pancancer/cancerGPT/CellReasoner/utils.py:404: FutureWarning: Series.__getitem__ treating keys as positions is deprecated. In a future version, integer keys will always be treated as labels (consistent with DataFrame behavior). To access a value by position, use `ser.iloc[pos]`\n",
      "  total_height = bottom[i]\n",
      "/public/workspace/caoguangshuo/public6/Pancancer/cancerGPT/CellReasoner/utils.py:413: UserWarning: set_ticklabels() should only be used with a fixed number of ticks, i.e. after set_ticks() or using a FixedLocator.\n",
      "  plt.gca().set_xticklabels(new_labels)\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 400x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plot_score_violin(output_data_df,fig_size=(4, 6))\n",
    "plot_score_stacked_bar(output_data_df, fig_size=(4, 6))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Reasoning mode"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processing batch 1/18\n",
      "Processing batch 3/18\n",
      "Processing batch 5/18\n",
      "Processing batch 7/18\n",
      "Processing batch 9/18\n",
      "Processing batch 11/18\n",
      "Processing batch 13/18\n",
      "Processing batch 15/18\n",
      "Processing batch 17/18\n",
      "Inference finished.\n"
     ]
    }
   ],
   "source": [
    "output_data = run_inference(\n",
    "    model=model,\n",
    "    tokenizer=tokenizer,\n",
    "    data=test_df, \n",
    "    batch_size=2, #GTX 4090 recommend 2\n",
    "    log_interval=2,\n",
    "    reasoning_mode=True,\n",
    "    has_label=True\n",
    ")\n",
    "output_data_df = pd.DataFrame(output_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "cell_name",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "response",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "labels",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "4ac7acff-58d4-4e6b-a1c7-77b43ee62120",
       "rows": [
        [
         "0",
         "ACCGTGCTGGAACG",
         " First, I need to recall what each gene does and in which cell types they're typically expressed.\n\nCD74 and HLA genes (like HLA-DRA, HLA-DRB1) are involved in antigen presentation, so that's a clue for B-cells or other immune cells. MS4A1 is CD20, a classic B-cell marker. CD79A and CD79B are components of the B-cell receptor complex. So this is definitely a B-cell related tumor.\n\nLooking at other markers: LTB (lymphotoxin beta), which is involved in lymphoid organ development. BANK1 is associated with B-cell activation. SPIB is a transcription factor important in B-cell differentiation. PTPRC (CD45) is a common leukocyte marker but not specific to B-cells. However, the presence of multiple B-cell markers like CD79A/B, MS4A1, CD19 (though not listed here, maybe other markers compensate), suggests it's a B-cell malignancy.\n\nNow, considering different B-cell tumors: Diffuse large B-cell lymphoma (DLBCL) has subtypes, some of which might express these markers. Germinal center B-cell (GCB) vs. activated B-cell (ABC) subtypes have different markers. But without more specific markers, hard to tell. Also, some genes like LMO2 are seen in precursor B-ALL, but that's less likely given the context.\n\nThe presence of genes like XBP1 might suggest plasma cell differentiation, but that's more common in multiple myeloma. However, if there's a mix, maybe a plasmacytoid dendritic cell? But the combination here seems more B-cell lineage.\n\nOther genes like CD3D and CD37 are T-cell markers, but those can sometimes be cross-expressed. However, the strong B-cell markers outweigh that. Maybe a case of mistaken identity?\n\nWait, looking again: The list includes CD52, which is found in various lymphocytes including T and B cells. CD70 is also expressed in activated T and B cells. Some overlap could exist.\n\nBut the key markers point towards B-cell origin. Given the high expression of multiple HLA class II genes, which are crucial for antigen presentation, along with B-cell receptor components (CD79A/B), surface immunoglobulins (though not listed here), and genes like MS4A1 (CD20), this strongly indicates a B-cell neoplasm.\n\nConsidering DLBCL as a possibility, but without more specific markers (like CD10 for GCB subtype, or CD23 for ABC), it's hard to specify. Alternatively, chronic lymphocytic leukemia (CLL)? But CLL usually expresses CD5, which isn't mentioned here.\n\nAnother angle: Some of the genes like IRF8 are involved in B-cell development. SPIB is another transcription factor in B-cells. BANK1 mutations are linked to autoimmune diseases but can be present in B-cell cancers.\n\nGiven all these B-cell markers and antigen processing genes, the most likely answer is a B-cell lymphoma. Since the question states tumor cells, the cell type would be B-cells. However, the exact subtype isn't specified because of the lack of specific markers. But the primary annotation based on the provided markers is:\n\nB cell",
         "B"
        ],
        [
         "1",
         "ACGTGATGCCATGA",
         " Now let's tackle this long list of genes.\n\nFirst, I notice several classic monocyte/macrophage markers here: CD14, CD68, CD163 (though not listed), HLA-DR genes (like HLA-DRA, HLA-DRB1), and things like FCER1G, TYROBP, which are involved in immune receptor signaling. There's also AIF1 (Allograft inflammatory factor 1) which is associated with macrophages. The presence of S100A proteins (S100A8, S100A9, etc.) might indicate some kind of myeloid activation, possibly granulocytes or monocytes.\n\nLooking further, there are genes related to antigen presentation, such as HLA-DPA1, HLA-DQB1, which are part of the MHC class II complex. Monocytes and macrophages express these to present antigens. Then there's CD74, an MHC class II molecular chaperone, reinforcing that antigen-presenting cells are involved.\n\nOther notable genes include LYZ (lysozyme), which is produced by monocytes and macrophages. FCGR2A and FCER1G are Fc receptors found on phagocytic cells. CCL5 and other chemokines (CCL3, CCL5) suggest involvement in immune cell recruitment, typical for monocytes.\n\nThere's also CD1C and CD1B, which are dendritic cell markers but can be expressed by monocytes under certain conditions. However, given the mix, maybe it's a subset of monocytes with some overlapping markers with dendritic cells.\n\nThe presence of genes like CSF1R (macrophage colony-stimulating factor receptor) points towards myeloid lineage cells. Genes involved in lysosomal activity (CTSB, CTSD) and lipid metabolism (APOE, though not listed here, but others like PLIN2) are common in macrophages.\n\nSome genes like SPP1 (osteopontin) and CD44 are seen in various immune cells but can be markers for activated monocytes. The inclusion of genes involved in inflammation (IL1B, TNF-related genes) aligns with monocyte functions during immune responses.\n\nHowever, there's a catch. Some markers like CD14 are typically used to distinguish monocytes from macrophages. But since the question specifies tumor cells, perhaps these are tumor-associated monocytes or a monocytic leukemia? Alternatively, maybe a macrophage-derived tumor, but the presence of both monocyte and macrophage markers could complicate things.\n\nWait, another angle: Monocytes can differentiate into macrophages upon migration to tissues. In tumors, monocytes might be recruited and then differentiate into tumor-associated macrophages (TAMs). So if the initial state is monocytes, but some markers point towards more differentiated states.\n\nBut looking at the list again, there's a mix of surface markers (CD14, CD16, CD68), MHC class II molecules, and lysosomal enzymes. This combination is more indicative of monocytes rather than fully differentiated macrophages. Also, genes like S100A8/A9 are expressed in neutrophils too, but combined with monocyte markers, it leans towards monocytes.\n\nAnother check: Are there any markers here that would suggest dendritic cells exclusively? Like CD1C and CD1B are sometimes on monocytes. Also, FCER1A is a dendritic cell marker but can be on monocytes in some contexts. Maybe the presence of both monocyte and DC markers indicates a transitional phase or a specific subtype.\n\nAlso, genes like CLEC10A and CLEC4A are C-type lectins found on monocytes. The presence of CD36 (a scavenger receptor) supports monocyte identity.\n\nPutting this all together, despite some overlapping markers with macrophages, the overall profile, especially when considering the context of tumor cells, seems to point towards monocytes. The answer should reflect the initial undifferentiated state before becoming macrophages in the tumor microenvironment.</think>Monocyte",
         "DC"
        ],
        [
         "2",
         "AGCGATTGAGATCC",
         " Now I need to analyze the user-provided gene list step by step to determine the tumor cell types.\n\nFirstly, I will scan through the gene list for key markers that may be associated with specific immune cells or tumors. For example, NK cell-related genes include GNLY (granulysin), GZMB (granzyme B), GZMA/GZMH (also granzymes), FCGR3A (CD16), KLRD1 (CD94), NKG7, PRF1 (perforin), etc., which are commonly found in cytotoxic lymphocytes such as NK cells and CD8+ T cells. However, it is necessary to distinguish between them.\n\nNext, other possible markers were noted: LYZ (lysozyme) is usually associated with myeloid cells such as monocytes/macrophages, but some NK cells may also express low levels of this gene. FCER1G and FCER1A are components of high-affinity IgE receptors and may be present in mast cells, basophils, or myeloid cells, but they can also appear in certain NK subpopulations. TYROBP (DAP12) is involved in signaling in NK cells and myeloid cells. The presence of CD52 suggests that there may be natural killer cells (NKs) or T cells, as both express CD52. SPON2 may be related to macrophage function, while CD7 may be seen in T cells or NK cells.\n\nThen, I noticed that there was a combination of cytotoxicity-related genes (GZMB, GZMA, PRF1, GNLY) along with NK-specific receptors (FCGR3A/CD16, KLRD1/CD94, NKG7). These genes are typically highly expressed in NK cells. In addition, interferon-stimulated genes (ISGs) such as IFITM family members (IFITM1, IFITM2) and IFI44L may indicate an inflammatory response or antiviral activity, which is common in NK cells activated in the tumor microenvironment.\n\nIn contrast, CD8+ T cells usually express more cytotoxic molecules like GZMB, PRF1, and also have specific surface markers such as CD8 itself, whereas here although there is CD52, there is no explicit CD8A/B gene, so it may not be mainly CD8+ T cells. Also, FCER1A is more likely to be associated with myeloid cells or innate lymphoid cells rather than conventional T cells.\n\nAlso, check for markers of other immune cells. For example, if there were a lot of B-cell markers (such as CD19, CD20) then it might be B-cell lymphoma, but there don't seem to be obvious ones here. Macrophage or monocyte markers such as CD14, CD68, AIF1 do not appear either. Mast cell markers such as tryptase (TPSAB1) and histamine receptor HIST1 weren't mentioned either.\n\nTaken together, the main markers point towards NK cells, especially considering the combination of granzymes, perforins, and activation-associated genes. Although there are some myeloid-related genes, the overall profile leans more towards NK cells. Therefore, after careful analysis, the most likely answer should be NK cells.</think>NK cell",
         "NK"
        ],
        [
         "3",
         "AGCGGGCTTGCCAA",
         " First, I need to identify which of these genes are known markers for specific immune cells.\n\nStart by looking at some of the key genes listed:\n\nCD74: often associated with antigen presentation, found in B cells and macrophages.\nMT2A: not sure about this one.\nHLA-DPA1: part of the MHC class II complex, common in antigen-presenting cells like dendritic cells, B cells, macrophages.\nLTB (lymphotoxin beta): involved in lymphoid organ development, possibly T or dendritic cells.\nIL7R: found in T cells, especially memory T cells.\nTNF: tumor necrosis factor, can be produced by various immune cells including macrophages and T cells.\nAIF1 (allograft inflammatory factor 1): expressed in macrophages.\nANXA1 (annexin A1): seen in neutrophils and monocytes.\nVIM (vimentin): a mesenchymal marker but also in fibroblasts and some immune cells.\nCXCR4: chemokine receptor, involved in homing of various immune cells.\nS100A4: linked to cancer progression and inflammation, present in myeloid cells.\nPLAC8: plasma membrane protein, may be in NK cells or cytotoxic T cells.\nFOS: early response gene, active in many activated cells.\nCD52: target of multiple therapies, present in lymphocytes.\nCD2: T cell marker.\nCD3D: T cell receptor component.\nIL32: cytokine, found in activated T cells and NK cells.\nSELL (L-selectin): initial homing receptor, found on naive T cells.\nS100A6: involved in inflammation, present in neutrophils.\nIFI44L, IFI6: interferon-inducible, suggest antiviral activity, could be NK or T cells.\nDUSP1: phosphatase, involved in T cell activation.\nFTL (ferritin light chain): expression varies.\nHLA-DPA1 again.\nA2M (alpha-2-macroglobulin): protease inhibitor, found in macrophages.\nIFITM2: interferon-induced, maybe in NK or T cells.\nSCGB3A1: sperm-associated antigen, not sure.\nFTH1: ferritin heavy chain.\nMALAT1: lncRNA, broadly expressed.\nCD48: interaction molecule, present on lymphocytes.\nKLRG1: killer cell lectin-like receptor G1, NK cells.\nIFITM2 again.\nCCR2: chemokine receptor, important for monocyte migration.\nPTPRC (CD45): leukocyte common terminal phosphate esterase, a pan-leukocyte marker.\nCD5: T cell marker, sometimes in regulatory T cells.\nCD44: adhesion molecule, found on memory T cells.\nGAPDH, ACTB, etc.: housekeeping genes, not specific.\nHLA-B, HLA-C, HLA-E: MHC class I molecules, present in all nucleated cells.\nCDKN2C: cyclin-dependent kinase inhibitor, various functions.\nOther genes like IL32, FOS, JUN, JUNB: immediate early genes responsive to activation signals.\nNow, considering that there's a mix of T-cell related genes (CD3D, IL7R, CD5), along with some myeloid markers (CD74, HLA-DPA1, AIF1) and NK-related genes (KLRG1, NKG7 isn't listed here but others like PLAC8 might be). The presence of both T-cell receptors and other immune cell markers suggests it's a type of T cell that has features overlapping with other immune cells.\n\nPossible combinations include:\n\nCD4+ T cells: They express CD3D, IL7R, CD4, and might have other markers depending on subtype.\nCD8+ T cells: Require CD8A/B, which aren't listed here. However, some cytotoxic molecules might be present.\nNK cells: But they typically lack CD3 and have different markers like NCAM1 (CD56), which isn't mentioned here.\nLooking further, the absence of CD8A/B and presence of CD4-related genes might lean towards CD4+ T cells. Also, genes like IL7R are more prominent in central memory T cells. Additionally, some genes like SELL (L-selectin) are associated with naive T cells, though they can downregulate upon activation.\n\nHowever, given the inclusion of CD48, CD52, and other activation markers, perhaps it's a subset of T cells that have been activated. Activated T cells would upregulate genes like FOS, JUN, and others involved in signaling pathways.\n\nAnother angle: Some genes like AIF1 (macrophage marker) and PTPRC (pan-leukocyte) might indicate some myeloid infiltration, but the majority of the markers point towards lymphocytes. Since CD3D is present, this is definitively a T cell. The combination of CD4-related genes and possible effector/memory markers (like IL32, TNF) might indicate an activated CD4+ T cell population.\n\nTherefore, after evaluating the markers, the most likely answer is that these genes correspond to a type of T cell, specifically CD4+ T cells, as they are a significant portion of the list, particularly when combined with other T cell-specific markers like IL7R and CD5. The presence of some myeloid-related genes might reflect co-expression due to activation or context, but the core identity points to T cells.</think>CD4",
         "Naive CD4 T"
        ],
        [
         "4",
         "AGGTCTGATTCTCA",
         " Now let's tackle this long list step by step.\n\nFirst, look at some key genes in the list. For example, CD14 is usually associated with monocytes or macrophages because it's a marker for these immune cells. Then there's CD68, which is also common in macrophages. Looking further, genes like FCGR3A (CD16) might indicate a subset of macrophages or NK cells, but combined with others, maybe it's more about myeloid lineage.\n\nLYZ (Lysozyme) is another classic macrophage marker. HLA-DRA and other HLA class II genes suggest antigen-presenting cells, which macrophages do when activated. Genes like S100A8 and S100A9 form calprotectin, often seen in neutrophils and monocytes during inflammation. But since there's a mix here, maybe not just neutrophils.\n\nThen there are genes like TYROBP and FCER1G, which are involved in immune receptor signaling, found in various myeloid cells including macrophages and dendritic cells. The presence of genes like CST3 (Cystatin C) and CTSS (Cathepsin S), which are lysosomal proteins, also points to phagocytic cells like macrophages.\n\nLooking at markers like CD83, which is associated with activated dendritic cells, but macrophages can express it under certain conditions too. Also, genes like AIF1 (Allograft inflammatory factor 1) are expressed in macrophages. PLAC8 is another gene linked to macrophage activation.\n\nSome genes like CD74 and CD83 relate to antigen presentation again supporting macrophages. There's also SPI1 (PU.1), a transcription factor critical for myeloid development, though I don't see it listed here, but other genes might compensate.\n\nNow, considering tumors: Macrophages are often present in the tumor microenvironment as part of the stroma. Tumor-associated macrophages (TAMs) can have different subtypes—M1 (pro-inflammatory) and M2 (anti-inflammatory/immune suppressive). The combination here might lean towards an M2 phenotype, given genes like ARG1 (not listed here), but other genes like MS4A7 (CD200) are involved in modulating immune responses typical in TAMs.\n\nAdditionally, genes like CCL5 (RANTES) are chemokines produced by macrophages to recruit other immune cells. The presence of multiple lysosomal enzymes (CTSB, CTSD, CTSL) suggests active phagocytosis and processing of pathogens, which is a function of macrophages.\n\nThere are also some genes related to lipid metabolism (like ACCELERATE family members), which might be involved in macrophage-derived exosomes or lipid modifications. This could fit with macrophage roles in lipid handling.\n\nPutting this all together, the majority of these genes are markers of myeloid lineage cells, specifically phagocytes. Given the tumor context, the most likely cell type is macrophages, possibly tumor-associated macrophages within the tumor stroma.</think>Tumor-associated macrophages",
         "FCGR3A+ Mono"
        ],
        [
         "5",
         "AGTACTCTCGGTAT",
         " Now let's tackle this long list of genes. The user wants to know which cell type it is based on these markers.\n\nFirst, I notice several HLA genes like HLA-DRB1, HLA-DPA1, HLA-DQB1, etc., which are part of the major histocompatibility complex (MHC) class II molecules. These are typically expressed in antigen-presenting cells because they present antigens to T cells. So maybe immune cells here?\n\nThen there are some T-cell related genes: CD3D, CD3E, CD3G, CD2, CD8A, CD8B, CD247 (part of the T-cell receptor complex), IL7R (common in memory T-cells). But wait, CD8A and CD8B are markers for cytotoxic T-cells (CD8+ T-cells). Also, NKG7 is often found in NK cells and cytotoxic T cells.\n\nLooking further, there's FCN1 (ficolin-1), which can be seen in natural killer cells and monocytes/macrophages. CD69 is an early activation marker for T-cells. There's also LTB (lymphotoxin beta), involved in lymphoid organ development, possibly from activated T-cells or dendritic cells.\n\nBut then there are genes like TYROBP, which is involved in signaling in myeloid cells but also found in T cells. However, the presence of multiple HLA class II genes might suggest more than just T cells. Maybe a subset of T cells that are activated? Or perhaps another immune cell type altogether.\n\nWait, there's also CD48, which is expressed on various leukocytes including T cells and platelets. Then there's IL32, which is associated with T-cell activation. FOS and JUN are immediate early genes involved in various cellular responses, including T-cell activation.\n\nLooking at other markers: CD52 is widely expressed on lymphocytes, so not specific. CD44 is a memory cell marker. CD8A/B again points to cytotoxic T cells. But there's also CD4? Hmm, if there were both CD4 and CD8 markers, that would be confusing. Let me check if any other T-cell subsets are indicated.\n\nThe combination of CD3 genes (CD3D, CD3E, CD3G) indicates T-cell identity. CD8A/B suggests cytotoxic T cells (CD8+). But there's also IL7R, which is more common in central memory T cells (TCM). CD69 is an activation marker. Also, genes like GIMAP7 and GIMAP4 are involved in T-cell survival.\n\nAdditionally, genes like NKG7 and CD96 (activation marker on NK and T cells). CCL5 is a chemokine produced by T cells during inflammation. DUSP2 is involved in T-cell receptor signaling.\n\nPutting this together: The presence of multiple T-cell markers (CD3, CD2, CD8A/B, IL7R, CD247) along with activation markers (CD69, FOS/JUN) and cytotoxicity-related genes (granzymes, perforins?) would point towards cytotoxic T cells. However, since there are also MHC class II genes, maybe it's a subset of T cells that are activated and presenting antigens, like effector memory T cells or cytotoxic T lymphocytes within a tumor context where they might upregulate MHC II due to interaction with tumor cells.\n\nAlternatively, could this be a mistake? Let me cross-check against other possibilities. For example, NK cells express CD56 (NCAM1) and NKG7, but those aren't listed here. Macrophages have different markers like CD68, CD14, which aren't present. Dendritic cells have CD83, CD11c, which aren't prominent here either.\n\nSo after considering all these markers, especially the combination of CD8A/B, CD3 complex, and T-cell activation genes, along with possible MHC II expression which might indicate activated state rather than resting, the most likely answer is cytotoxic T cells. The key indicators are the CD8 lineage and T-cell receptor components.</think>Cytotoxic T cell",
         "Memory CD4 T"
        ],
        [
         "6",
         "ATACGGACTATGCG",
         " Now let's tackle this problem step by step.\n\nFirstly, the user provided a long list of genes that are said to be highly expressed in a certain type of tumour cell, and wants me to determine the cell type based on these markers. The key is to identify which of these genes are known markers for specific immune or other cell types.\n\nLooking at the gene list, several stand out as classic MHC class II molecules: HLA-DRA, HLA-DRB1, HLA-DPA1, HLA-DQB1, HLA-DQA1, HLA-DPB1, etc. These are involved in antigen presentation and are typically expressed in antigen-presenting cells (APCs) like dendritic cells, macrophages, and B-cells. This suggests the tumour might originate from an APC.\n\nNext, there are B-cell related genes such as CD79A, CD79B, MS4A1 (which encodes CD20), CD37, CD48, CD72, etc. CD79A and CD79B form part of the B-cell receptor complex, while MS4A1 is a well-known marker for mature B-cells. Additionally, genes like BANK1, FCER1G, and FCER2 (CD23) are also associated with B-cells. However, FCER2 is interesting because it codes for CD23, which is commonly found on the surface of activated B-cells and some myeloid cells but can also be a marker for plasma cells.\n\nOther notable genes include LTB (lymphotoxin beta), which plays a role in lymphoid organ development and is produced by germinal centre B-cells. Genes like AIF1 (Allograft inflammatory factor 1) are expressed in various immune cells, including B-cells. SELL (CD62L) is a homing receptor involved in B-cell trafficking.\n\nThe presence of genes like BCL6 would suggest germinal centre B-cells, but it isn't listed here. However, IRF5 is present, which is involved in the activation of plasmacytoid dendritic cells and B-cells, particularly in the germinal centre reaction. Additionally, genes like CXCR4 and CXCL16 may relate to B-cell migration and chemotaxis.\n\nNow, considering the combination of MHC class II genes, B-cell markers, and other immune-related genes, along with the absence of strong T-cell markers (like CD3D/CD3E), it seems more likely that the tumour originates from B-cells rather than T-cells. The inclusion of CD23 (FCER2) and possibly other markers like CD10 (not listed here) could indicate germinal centre origin, but without CD10, maybe post-germinal centre?\n\nHowever, another angle: some studies show that chronic lymphocytic leukaemia (CLL) cells express high levels of MHC class II and certain B-cell markers. But CLL usually has a different gene expression profile, e.g., CD5+ often, whereas here there's no CD5. Alternatively, multiple myeloma? But that's plasma cell-derived, lacking plasma cell markers like CD138 (SDC1).\n\nAlternatively, looking for markers suggestive of a particular subtype:\n\nHLA-DR genes are highly expressed in normal memory B-cells compared to naive. Also, genes like CD69 (early activation marker), CD48 (interaction molecule), and others might point towards activated B-cells.\n\nAnother possibility is a B-cell lymphoma, such as diffuse large B-cell lymphoma (DLBCL). DLBCL subtypes include Germinal Centre B-cell-like (GCB) and Activated B-cell-like (ABC). GCBs would have higher expression of genes like LMO2, BCL6, and IRF4, whereas ABCs might have more MYC, MUM1, etc. Here, IRF5 is present, which can be seen in both, but not BCL6. However, given the presence of MHC II and other B-cell markers, perhaps the GCB subtype is indicated.\n\nAdditionally, genes like LCP1 (L-plastin) are involved in cytoskeletal rearrangements in activated B-cells. CORO1A (Coronin 1A) is involved in cell motility, again consistent with activated B-cells.\n\nConsidering all these factors—high MHC II, B-cell markers, possible germinal centre markers (LTB, IRF5)—the most plausible conclusion is that the tumour cells are derived from germinal centre B-cells, hence the annotation should be Germinal centre B-cell.</think>Germinal centre B-cell",
         "B"
        ],
        [
         "7",
         "ATCTTTCTTGTCCC",
         " Now let's tackle this long list of genes. The user wants to know which tumour cell type it is based on these markers.\n\nFirstly, I notice that there are many cytotoxic-related genes in the list, such as GNLY (granulysin), GZMB/GZMA (granzymes B/A), PRF1 (perforin), FCGR3A (CD16), NKG7, etc., which are typically associated with killer cells like NK cells or CD8+ T cells. However, CD8A is present here, which points towards CD8+ T cells. Then there are genes like CD37, CD247 (CD3ζ chain), which are part of the T-cell receptor complex, supporting the idea of T-cells.\n\nNext, looking at other markers: KLRD1 (CD94) might suggest NK cells, but combined with CD8A/CD3, it's more likely to be CD8+ T cells. Also, genes like FCER1G could be involved in immune regulation, but not sure about its specific role here. There's also HLA class I and II genes, but since the answer is supposed to be a tumour cell type, maybe it's a T-cell lymphoma?\n\nPutting this all together, the presence of both CD8A and T-cell receptor-related genes suggests CD8+ T cells. But wait, some genes like NKG7 can also be found in NK cells. However, given the combination of CD8A and CD3-related genes, CD8+ T cells seem more plausible. So after considering possible confounding factors, the conclusion should still point to CD8+ T cells.</think>CD8",
         "NK"
        ],
        [
         "8",
         "CAAAGCACCGTAAC",
         " First, I need to recall what each gene does and which cell types they're associated with.\n\nHLA-DRA, HLA-DRB1, HLA-DPA1, etc.: These are part of the MHC class II complex. Antigen-presenting cells like B-cells, dendritic cells have high expression.\nCD74: Involved in MHC class II antigen presentation, again B-cells and APCs.\nMS4A1 (CD20): Marker for B-cells.\nCD79A/CD79B: Part of the B-cell receptor complex.\nBANK1: Involved in B-cell activation and signaling.\nFCRL family genes: Found in B-cells and some myeloid cells.\nLYZ: Lysozyme, often in myeloid cells but also in activated B-cells.\nGPR183: Associated with B-cell migration.\nCXCR4: Chemokine receptor involved in B-cell trafficking.\nTIGIT: Usually in immune checkpoint regulation, maybe regulatory T cells or NK cells, but can be in B-cells too.\nIL32: Inflammatory cytokine, found in various immune cells including B-cells.\nSELL (CD62L): Homing receptor for lymphocyte migration.\nFOS/JUNB: Early response genes after activation.\nCD27: Markers for memory B-cells.\nCD48: Interaction molecule in B-cell activation.\nRUNX3: Transcription factor in B-cell development.\nVIM (Vimentin): Mesenchymal markers but also in activated B-cells.\nOther genes like BANK1, FCER2, CD53, which are B-cell related.\nNow, considering tumors: If these genes are highly expressed, it might indicate a B-cell malignancy. The presence of MHC II genes suggests an activated state since resting B-cells usually have lower MHC II. Also, genes like CD27 and CD40 are involved in B-cell activation and survival. Some genes like LYZ and VIM could be due to tumor microenvironment interaction rather than cell type-specific.\n\nPutting this together, the combination points towards a B-cell origin, likely a B-cell lymphoma or leukemia where these genes are overexpressed. Since there's no mention of plasma cell markers (like SDC1) or other specific markers, the most likely answer is that these genes are characteristic of B-cells.</think>B cell",
         "B"
        ],
        [
         "9",
         "CCCTAGTGCAAAGA",
         " Now let's tackle this long list of genes.\n\nFirst, I notice several T-cell related genes like CD3D, CD3E, CD3G, CD2, CD4, CD8 (though not CD8 here), and CD247 (part of the CD3 complex). That points to T-cells. Then there are activation markers like CD69, which is early activation, and CD45RA vs. CD45RO. The presence of CD45RA might suggest central memory T cells since they can express both CD45RA and CD45RO.\n\nLooking at other markers: LYZ is lysosome-associated, maybe in cytotoxic granules? But also seen in macrophages. However, the absence of typical macrophage markers like CD14 or CD68 makes me think it's more about T-cells. Genes like GZMB, PRF1, and TNFRSF family members could indicate cytotoxic function, but I don't see those here. Instead, there's FASLG, which is involved in apoptosis, often in activated T-cells.\n\nThere's also HLA class II genes like HLA-DRA, which might be confusing because activated T-cells usually downregulate MHC class II. But maybe this is a specific subset or context where they're upregulated. Alternatively, maybe it's a regulatory T-cell subset?\n\nWait, the presence of FOXP3 would suggest regulatory T-cells, but I don't see FOXP3 in the list. Hmm. Maybe other regulatory markers? Like IL2RA (CD25) isn't listed here. But there's CD7, which is found on some T-cell subsets.\n\nAnother angle: looking for genes that are specific. For example, CD4+ T-cells might have different markers compared to CD8+. Let's check if there are any CD8-related genes here. Not seeing CD8A or CD8B, so maybe it's CD4+.\n\nAlso, genes like SELL (L-selectin) are present, which is typically on naive T-cells. If they're expressing CD45RA and SELL, that suggests naive CD4+ T-cells. Naive CD4+ T-cells would have low expression of activation markers like CD69 unless recently activated. So maybe this is a mix of naive and some activated markers due to activation state post-antigen recognition?\n\nBut wait, the user says these are highly expressed in a certain tumor cell type. Could this be a T-cell lymphoma? Like peripheral T-cell lymphoma? But PCPs usually have a broad phenotype. Or maybe chronic activation leads to expression of some activation markers.\n\nAlternatively, maybe it's a Th1 or helper T-cell subset. CD4+ T-cells can have different subtypes depending on cytokine signals. For example, interferon-gamma producing CD4+ T-cells (Th1) might upregulate certain genes.\n\nLooking again: IL3RA (CD123) is present, which is associated with plasma cells, but not sure how that fits. Wait, maybe IL3RA is just part of the list and not relevant.\n\nThe presence of genes like CD74, which is involved in MHC class II antigen presentation, might suggest interaction with antigen-presenting cells, but since the tumor cells themselves are expressing it, maybe the tumor cells are of B-cell origin (like Hodgkin's lymphoma)? But the initial question mentions T-cell markers.\n\nAlternatively, maybe it's a T-cell leukemia with aberrant gene expression. In acute lymphoblastic leukemia (ALL), CD4+ cases exist, but the gene expression profile might show some markers cross-over.\n\nGiven all these conflicting signals—naive CD4+ T-cells, activated markers, possible regulatory T-cells, but no definitive FOXP3—maybe the answer lies in the combination of naive CD4+ T-cell markers along with some activation genes due to tumor microenvironmental cues.\n\nFinal answer:Naive CD4+</think>Naive CD4+</answer>",
         "Memory CD4 T"
        ],
        [
         "10",
         "CCTACCGACTCTTA",
         " First, I need to identify which of these genes are known markers for specific immune cells.\n\nStart by looking at some of the key genes listed:\n\nS100A9 and S100A6: These are part of the S100 calcium-binding protein family and are often associated with myeloid cells like neutrophils and monocytes.\nLYZ (Lysozyme): Typically found in macrophages and other myeloid cells.\nCD74 and HLA-DRA/HLA-DRB5: These are involved in antigen presentation, suggesting dendritic cells or macrophages.\nLTB (Lymphotoxin Beta): Associated with lymphocyte attraction but also produced by macrophages.\nCD69: An early activation marker found on various leukocytes, including T-cells and macrophages.\nCCL5 (RANTES): Chemokine involved in attracting monocytes and memory T-cells.\nVIM (Vimentin): Markers of mesenchymal cells, but also seen in macrophages.\nCXCR4: Chemokine receptor involved in monocyte trafficking.\nFOS and JUNB: Early response genes expressed upon cell activation.\nCD3-related genes (CD3D, CD3G, CD3E): Part of the T-cell receptor complex, so presence here might indicate T-cells, but since other markers suggest myeloid lineage, maybe regulatory T-cells?\nSPIB: Transcription factor important in megakaryocytic differentiation, but also in monocytes/macrophages.\nOther genes like CST3 (Cystatin C), LSP1 (Leukocyte-specific Intein-containing Protein 1), and FCGR3B (CD16) are also linked to myeloid cells.\nNow, consider possible cell types that could express these genes simultaneously. Neutrophils have some overlapping markers with monocytes (like S100 proteins). Monocytes can differentiate into macrophages or dendritic cells. The presence of both T-cell related genes (CD3) and myeloid markers complicates things. However, if the majority point towards monocytes, especially when considering genes like CD14 is missing but others like CD68 or CD16b (FCGR3B) are present.\n\nAlso, genes like CEACAM3, CD14, and CD16a/b are typical monocyte markers. Checking the list, there's FCGR3B (CD16b), which is a subset of monocytes. Also, S100A9/A6 as mentioned earlier. Additionally, genes like CST3, LYZ, and CD74 support this.\n\nAnother angle: Some genes like CD48 and CD53 are pan-leukocyte, so not specific. But combined with the others, it points more towards monocytes than other immune cells.\n\nTherefore, putting it all together, despite some T-cell related genes possibly indicating activated T-cells, the overall gene expression profile aligns better with monocytic lineage cells, likely monocytes given the presence of CD16b and absence of more definitive T-cell markers. Therefore, the answer should be Monocytes.</think>Monocytes",
         "Naive CD4 T"
        ],
        [
         "11",
         "CGGCGAACTACTTC",
         " Now let's tackle this long list step by step.\n\nFirst, I notice several granzyme-related genes: GNLY, GZMB, GZMA, GZMH, GZMM. Granzymes are enzymes released by cytotoxic lymphocytes like NK cells and CD8+ T cells, so that's a hint towards cytotoxic cells.\n\nThen there's CD74, which is involved in antigen presentation but can also be found in activated T cells. However, its presence here might indicate some kind of immune cell interaction or activation.\n\nLooking at other markers: CD3E is part of the T-cell receptor complex, suggesting T-cells. But wait, if it's CD3E, then maybe it's CD4 or CD8? The presence of both CD3E and CD8-related genes (like CD247, which is part of the CD3 complex) suggests T-cells. However, CD4 isn't listed here. Hmm.\n\nWait, there's also CD7, another T-cell marker. So maybe T-c cells. But then why the presence of NK cell markers? Let me check again. The list includes genes like NKG7, KLRD1 (CD94), and FCGR3A (CD16). These are typically associated with NK cells or natural killer-like T cells (NK-T cells).\n\nBut NK cells usually have more specific markers like NCAM1 (CD56), which isn't listed here. However, the combination of CD3E with granzymes and NK-associated genes could point to NK-T cells or a similar subset.\n\nAlso, genes like PRF1 (perforin) are present, which is another cytotoxic molecule found in NK cells and CD8+ T cells. The presence of multiple granzyme genes and perforin supports cytotoxic function.\n\nHLA-DPB1 is an MHC class II gene, which might suggest antigen-presenting cells, but given the other markers, it's possible this is a memory T-cell subset.\n\nLooking for other clues: S100A8 and S100A4 are calcium-binding proteins often seen in myeloid cells, but they can also be expressed in activated T cells. The presence of FCER1G and TYROBP might relate to innate immunity receptors, which can be co-expressed in certain T-cell subsets.\n\nThe presence of CD69 is a marker of early T-cell activation. CD52 is widely expressed in lymphocytes, including T cells. IL32 is a pro-inflammatory cytokine gene, common in activated T cells.\n\nPutting this together: There's a mix of T-cell markers (CD3E, CD7, CD247) along with cytotoxic/granzyme genes (GNLY, GZMB, etc.), and some NK-associated genes (NKG7, KLRD1). This combination might not fit classic CD8+ or NK cells alone. Instead, it could represent a T-cell subset with NK features, such as NK-T cells or a specific T-cell lymphoma subtype where such markers are co-expressed.\n\nAdditionally, genes like FCRL6 (Fc receptor-like protein 6) are associated with certain T-cell subsets. Also, the presence of genes like LATM5 (lymphocyte antigen 6 family member M) is linked to cytotoxic T cells.\n\nAnother angle: Some of the genes mentioned, like CD52, are targets for therapies like alemtuzumab, which is used in chronic lymphocytic leukemia. However, that's more about the cell surface marker rather than the gene itself.\n\nConsidering all these factors, especially the combination of CD3E with granzymes and NK-associated genes, the most likely answer is a T-cell origin, possibly a cytotoxic T-cell lymphoma or a T-cell subset with NK features. Given the context of the question, the final annotation would be:\n\nCD8+ T cells</think>CD8",
         "NK"
        ],
        [
         "12",
         "CGTGTAGAGTTACG",
         " First, I need to recall what each gene does and which cell types they're associated with.\n\nGNLY: Granzyme A/B, found in cytotoxic lymphocytes like NK cells and CD8+ T cells.\nS100A9 and S100A8: Calprotectin subunits, often seen in myeloid cells, but also in neutrophils.\nGZMB: Granzyme B, again pointing towards cytotoxic T or NK cells.\nLYZ: Lysozyme, common in monocytes/macrophages and microglia.\nCD74: Antigen-presenting molecules, found in various immune cells including macrophages.\nGZMA/GZMH: Granzymes A/H, as mentioned earlier, for cytotoxic cells.\nFCGR3A/FCER1G: Fc receptors involved in phagocytosis, macrophages, dendritic cells.\nPRF1 (Perforin): Key cytolytic molecule in NK cells and CD8+ T cells.\nHOPX: More specific to macrophages, especially M2-like.\nPTGDS: Prostaglandin D2 synthase, linked to Th2 responses and mast cells.\nTYROBP: Tyrobp signaling in myeloid cells, like macrophages.\nIL2RB: Part of cytokine receptors, present in many immune cells.\nCD3E: T-cell receptor component, so presence here might suggest T-cells, but combined with others?\nFCER1G: Mast cell marker.\nIGFBP7: Inflammatory fibroblasts or macrophages.\nPLAUR: U-plastases, involved in tissue remodeling, seen in macrophages.\nPLEC: Plakoglobin, but not sure about this one.\nCD52: Found in lymphocytes, including T and B cells.\nSRGN: Serglycin, proteoglycan in granules, NK and T cells.\nITGB2: Integrin beta 2, adhesion molecules, macrophages.\nS100A6/A4: Calcium-binding proteins, maybe in macrophages.\nCCL4/CCL3: Chemokines produced by macrophages during inflammation.\nDUSP2/DUSP1: Phosphatases regulating stress response, various cells.\nCD7: T-cell marker, but also some NK cells.\nLAPTM5: Myelin-associated, but also in macrophages.\nCTSB/CTSD: Cathepsins, lysosomal enzymes, active in macrophages.\nIL2RG: Common gamma chain, part of multiple cytokine receptors.\nCD37: B-cell marker, but also in NK cells.\nPSAP: Peptidase, possibly in cytotoxic cells.\nAPOBEC3G: DNA editing enzyme, activated upon viral infection, found in various immune cells.\nHLA genes: Antigen presentation, so immune cells like macrophages, dendritic cells.\nLY6E: Leukocyte-specific protein, maybe in NK cells.\nCD48: Interaction molecule in immune synapses, present in various leukocytes.\nIFITM2: Interferon-induced, broad expression.\nCYTIP: Cytoplasmic targeting, maybe in macrophages.\nOther genes like FOS/JUN/KLF2: Stress response genes, active in activated immune cells.\nNow, considering the combination:\nHigh expression of granzymes (GZMB, GNLY) suggests cytotoxic function, typical of NK cells and CD8+ T cells. However, other markers like FCGR3A (CD16b), FCER1G (mast cell), and PTGDS (mast cell) point towards myeloid lineage. The presence of HOPX, IGFBP7, and PLAUR leans towards macrophage-related markers. Additionally, genes like LYZ, CCL4, and PRF1 can be expressed in both NK cells and macrophages. The absence of clear T-cell receptor components like CD3D or CD8A complicates things. Also, CD74 is more associated with antigen presentation, which macrophages do. Considering all these factors together, it seems that despite initial thoughts leaning towards NK cells due to granzymes, the strong presence of macrophage-associated genes suggests that the tumor cells have a myeloid origin, specifically macrophages. Therefore, the correct annotation would be myeloid.</think>Myeloid",
         "NK"
        ],
        [
         "13",
         "CTCCACGAGAGATA",
         " Now let's tackle this long list of genes.\n\nFirst, I notice several HLA genes: HLA-DRA, HLA-DRB1, HLA-DPA1, HLA-DQB1, etc. These are part of the major histocompatibility complex (MHC) class II molecules, which are typically expressed in antigen-presenting cells like dendritic cells, macrophages, and B cells. But since there's also CD74, which is involved in MHC class II antigen presentation, that supports an antigen-presenting cell type.\n\nLooking for dendritic cell markers: CD1 family genes stand out. CD1C is listed here, along with CD1D. CD1 molecules present lipids to T cells, which dendritic cells do. Also, FCER1A (also known as CD200) is another key marker for conventional dendritic cells (cDC). FCER1G is involved in Fc receptor signaling, common in myeloid cells including cDCs.\n\nOther genes associated with dendritic cells include CLEC10A (CD301), which is a cDC marker. LYZ encodes lysozyme, found in myeloid cells. CD68 is a lysosome-associated membrane protein often seen in monocytes/macrophages but can be expressed by some dendritic cells too. However, CD68 isn't specific to cDCs.\n\nGenes like GNLY (granulysin) are usually in cytotoxic T or NK cells, but maybe cross-checked against other markers. S100A9 and S100A8 form calprotectin, commonly in neutrophils and monocytes. Their presence might indicate an inflammatory environment, but not ruling out dendritic cells if co-expressed with other markers.\n\nNow, checking for absence of conflicting markers. No clear signs of T-cell receptors or B-cell markers like CD19/CD20. The presence of immune-related genes like TYROBP (DAP12) which is involved in signaling in myeloid cells. Also, genes like CLEC7A (Dectin-1) which is a myeloid cell receptor.\n\nSome genes like CD83 are activation markers for dendritic cells. CD86 is a co-stimulatory molecule expressed upon activation. The presence of multiple HLA class II genes reinforces antigen-presenting function.\n\nPutting it all together: high expression of MHC class II genes, CD74, CD1C, CD1D, FCER1A/G, CLEC10A, along with various lysosomal and granule proteins suggests a classic dendritic cell lineage. The lack of strong T or B cell-specific markers supports this. Therefore, the cell type is likely classical dendritic cells.</think>Classic dendritic cell",
         "DC"
        ],
        [
         "14",
         "CTGAGAACGTAAAG",
         " Now let's tackle this step by step. The user provided a long list of genes that are highly expressed in a certain tumor cell type and wants me to determine which cell type it is.\n\nFirst, I'll start by scanning through the gene list for any obvious markers. I notice several genes related to cytotoxic function: GNLY (granulysin), GZMB (granzyme B), GZMA (granzyme A), GZMH (granzyme H), PRF1 (perforin). These are typically found in killer lymphocytes like NK cells or cytotoxic T cells. Then there's NKG7, which is also associated with natural killer cells and cytotoxic T cells. KLRB1 (CD161) is present here too, which can be found in NK cells and some T-cell subsets.\n\nLooking further, I see FCGR3A (CD16), which is another marker for NK cells as they express CD16. HLA genes like HLA-DRA, HLA-DPA1, HLA-B, HLA-C, HLA-A, HLA-E are present. These are part of the major histocompatibility complex (MHC) class II and class I molecules. MHC class I molecules are important for antigen presentation, so their presence might indicate active immune cells. However, MHC class II is usually more prominent in antigen-presenting cells like dendritic cells or macrophages, but some activated T cells or NK cells might express them under certain conditions.\n\nOther genes like CCL5, CCL4 are chemokines involved in attracting immune cells. SELL (CD62L) is a homing receptor found on memory T cells and naive NK cells. CD52 is widely expressed on lymphocytes, including T and NK cells. LCK and FYN are kinases critical for T-cell receptor signaling, but also important for NK cell activation. TYROBP is a signaling molecule involved in NK cell receptor signaling.\n\nThere's also CD247, which is part of the T-cell receptor complex, suggesting a T-cell origin. However, some studies show that NK cells can also express certain T-cell markers under specific circumstances. For example, in some literature, NK cells might co-express CD3, though I'm not sure if that's common. Alternatively, maybe this is a case of atypical NK cells or a different subset.\n\nWait, looking back, the presence of both T-cell markers (like CD3-related genes) and NK-specific markers (like NKG7, GNLY, KLRB1) could be confusing. But perhaps the key here is the combination of granzymes, perforin, and CD16/CD62L. Also, genes like ZFP36 (which regulates mRNA stability) and others involved in apoptosis (like BCL11B) might be relevant.\n\nAnother angle: Some tumors arise from NK cells themselves. For instance, NK-cell leukemias or lymphomas would have high expression of NK markers. Given the extensive list, maybe this is a tumor derived from NK cells rather than T-cells. The presence of genes like NCAM1 (though not listed here) isn't necessary, but other markers like CD16 (FCGR3A) are present.\n\nAlternatively, considering the diversity of genes, maybe it's a malignant transformation of a cytotoxic lymphocyte population. In some cases, NK cells can become neoplastic, expressing cytotoxic granule proteins along with activation markers. The combination of HLA class I/II, cytotoxic enzymes, and absence of typical oncogenes might point towards an NK-cell derived tumor.\n\nIn conclusion, after evaluating the markers: cytotoxic granules (GZMB, GNLY), NK-specific receptors (NKG7, KLRB1), MHC class I/II, and absence of strong T-cell receptor signaling components (no CD3E), the most likely answer is NK cell.</think>NK cell",
         "NK"
        ],
        [
         "15",
         "GAAAGATGCTGATG",
         " Now let's tackle this long list step by step.\n\nFirst, I'll scan through the gene list to look for any obvious markers that stand out. For example, CD68 is commonly associated with macrophages, which makes me think of myeloid cells. Then there's HLA-DRA, HLA-DRB1, etc., which are part of the MHC class II complex, often involved in antigen presentation, again pointing towards immune cells like dendritic cells or macrophages.\n\nLooking further, I see FCGR3A (CD16a), which is found on NK cells and some monocytes/macrophages. There's also LYZ (lysozyme), which is present in neutrophils and monocytes. Then there are several S100 proteins: S100A8, S100A9, S100A4, etc., which are calcium-binding proteins often linked to inflammation and neutrophils, but also seen in monocytes and macrophages.\n\nWait, but there's also CD74 and CD79B. CD74 is part of MHC class II, so still immune-related. CD79B is part of the B-cell receptor complex, but maybe here it's not about B-cells? Maybe just part of the broader immune signature?\n\nThen there's MS4A family genes like MS4A7 and MS4A4A. MS4A4A is CD20, a classic B-cell marker, but MS4A7 might be more specific. Hmm, maybe not definitive for B-cells. Alternatively, maybe these are part of a different pathway.\n\nLooking at other genes: CST3 (cystatin C) is associated with macrophages. AIF1 (allograft inflammatory factor 1) is another macrophage marker. FCER1G is part of the Fc epsilon receptor, found in various immune cells including mast cells and macrophages.\n\nThere's also genes like TYROBP, which interacts with signaling molecules in immune cells. SPI1 (PU.1) is a transcription factor critical for myeloid development. That's a big hint towards myeloid lineage.\n\nAdditionally, genes like LTB (lymphotoxin beta) are involved in lymphoid organ development but can be produced by macrophages. HMOX1 (heme oxygenase 1) relates to oxidative stress responses, common in activated macrophages.\n\nNow, considering tumors, if these genes are highly expressed in tumor cells themselves rather than infiltrating immune cells, then perhaps it's a sarcoma with myofibroblasts? But the presence of multiple macrophage-specific markers like CD68, AIF1, and FCGR3A leans more towards myeloid origin.\n\nHowever, some genes like CD3E and CD48 are T-cell related, but those could be contaminants or maybe part of a tumor microenvironment interaction. But since the question states these are highly expressed within the tumor cells, maybe they're expressing some immune genes aberrantly?\n\nAlternatively, maybe it's a histiocytic sarcoma, which are derived from monocyte-macrophage lineage. Histiocytic sarcomas express markers like CD68, CD163, S100A8/A9, etc. The list includes S100A8, S100A9, CD68, FCGR3A, which aligns with histiocytic features.\n\nAnother angle: the presence of genes like FCGRT (Fc gamma receptor), which is involved in antibody-dependent cellular cytotoxicity, typical of macrophages. Also, genes like MNDA (myeloid cell nuclear differentiation antigen) are specific to myeloid cells.\n\nPutting this all together, the strongest indicators point towards a myeloid lineage, specifically a histiocytic tumor. The combination of MHC class II genes, lysosomal enzymes (CTSB, CTSS), macrophage markers (CD68, AIF1), and S100 proteins strongly supports this conclusion. Therefore, the answer should be histiocytic.</think>Histiocytic",
         "FCGR3A+ Mono"
        ],
        [
         "16",
         "GAACCTGAACGTGT",
         " Now let's tackle this long list of genes.\n\nFirst, I notice several cytotoxicity-related genes: GZMA, GZMK, PRF1 (perforin), and NKG7. These are often found in natural killer (NK) cells or cytotoxic T lymphocytes (CTLs). But wait, there's also CD83 and CD8? Hmm, maybe not CD8 though. Let me check again. The presence of CD83 might suggest dendritic cells or activated T cells. Wait, but there's also CD3D and CD3E, which are part of the T-cell receptor complex. So maybe T-cells?\n\nLooking further, there's CD4 here too. That's confusing because CD4 is typically on helper T-cells. But some subsets might express both CD4 and CD8. Also, genes like IL7R are more common in memory T-cells. Then there's CD52, which is present in many lymphocytes including T and B cells.\n\nOther markers: CCL5 (RANTES) is chemokine involved in immune response. CD69 is an early activation marker for T-cells. CD2 and CD7 are surface proteins on T-cells. TYROBP is involved in signaling in NK cells and macrophages. But since it's a tumor, maybe a leukemia?\n\nNow, considering tumors derived from T-cells, such as T-cell lymphomas. In particular, precursor T-cell lymphoblastic lymphoma or leukemia might express high levels of these genes. Pre-T cells would have different markers, but mature T-cells might include CD3, CD4/CD8, and cytotoxic molecules.\n\nAlso, genes like LCK, ZAP70, and LAT are kinases involved in T-cell receptor signaling. CD48 is a co-stimulatory molecule on T-cells. The presence of multiple CD molecules supports T-cell origin.\n\nAdditionally, genes like FOS, JUN, and JUNB are immediate early genes that can be induced upon T-cell activation. SOCS3 is involved in negative regulation of cytokines, which makes sense in activated T-cells.\n\nThere's also HLA class II genes like HLA-DPB1, which are usually in antigen-presenting cells like dendritic cells or B-cells, but some activated T-cells might express them. However, the strong presence of CD3 genes (CD3D, CD3E) points towards T-cells.\n\nPutting this all together, the combination of T-cell markers (CD3, CD4, CD8, LCK, ZAP70), cytotoxic granule proteins (GZMA, GZMK, PRF1), and activation markers (CD69, CD83) suggests that these genes are likely from a T-cell malignancy, specifically a T-cell lymphoma or leukemia. Given the context of a tumor with these markers, the most probable answer is that the cell type is CD4+ T-cells, possibly in the context of a T-cell lymphoma where these genes are overexpressed.</think>CD4",
         "Memory CD4 T"
        ],
        [
         "17",
         "GAAGCTACGAATGA",
         " First, I need to identify key markers from the list provided by the user.\n\nFirstly, I will scan through the gene list for known macrophage markers. For example, CD68, LYZ (Lysozyme), and FCGR1A (Fc gamma receptor) are common markers for monocytes/macrophages. In addition, HLA-DRA, HLA-DRB1, etc., belong to MHC class II molecules, which may indicate antigen-presenting cells such as dendritic cells or macrophages. There is also S100A8 and S100A9, which form calprotectin and are commonly found in myeloid cells, especially in inflammation.\n\nNext, I need to rule out other possibilities. For example, if there were more T-cell related genes like CD3, CD4, or CD8, then it might be a T-cell, but there isn't any obvious presence here. Similarly, B-cell markers like CD19 or CD20 aren't prominent either. Instead, there's FCER1G, which can be associated with innate immune cells, including natural killer cells and macrophages.\n\nThen look at some other genes: AIF1 (Allograft inflammatory factor 1) is expressed in macrophages. CST3 (Cystatin C) is also associated with macrophages. There is also CD14, although not listed here, there may be other alternative markers. In addition, things like MS4A6A and MS4A7 are members of the MS4A family that may play a role in macrophage function.\n\nIn addition, some interferon-stimulated genes (ISGs) like IFIT2, IFIT3, and MX2 appear in the list, which may suggest an activated state, such as infection or chronic inflammation, which is consistent with the characteristics of macrophages involved in immune regulation.\n\nTaken together, most of these genes point to myeloid lineage cells, particularly macrophages. Considering possible subtypes, conventional dendritic cells (cDCs) vs. macrophages may have different markers. For example, cDC usually expresses CD1c, CD11c, etc., whereas macrophages may express higher levels of CD68, LYZ, etc. In addition, some genes like TYROBP (DAP12) are associated with signaling in myeloid cells, supporting the possibility of macrophages.\n\nTherefore, after careful analysis, the combination of these genes is more consistent with the profile of macrophages rather than other immune cell types.</think>Macrophage",
         "CD14+ Mono"
        ],
        [
         "18",
         "GAGGTACTACTCAG",
         " Now let's tackle this problem step by step.\n\nFirstly, I need to carefully read through the list of genes provided by the user to see if any stand out as markers for specific immune cells. For example, CD74 is often associated with antigen presentation and is commonly found in macrophages and dendritic cells. Then there's HLA-DRA, which is part of the MHC class II complex, again pointing towards antigen-presenting cells like macrophages or dendritic cells. Additionally, genes like FCER1G (Fc epsilon receptor Ig) and TYROBP are involved in immune receptor signaling and are common in myeloid cells such as monocytes and macrophages.\n\nNext, looking at other genes: LYZ encodes lysozyme, an enzyme produced by macrophages and neutrophils. AIF1 (Allograft inflammatory factor 1) is also expressed in macrophages. CST3 (Cystatin C) is another gene linked to macrophage activity. Then there's S100A family members like S100A8 and S100A9, which form calprotectin and are typically expressed in neutrophils and monocytes/macrophages during inflammation. However, since the question specifies tumor cells, maybe it's more about tissue-resident macrophages?\n\nAlso, genes like FPR1 (Formyl peptide receptor 1) are involved in chemotaxis and are present in various immune cells, including macrophages. The presence of multiple lysosomal enzymes such as CTSS, CTSL, and CTSB suggests active phagocytosis and processing of pathogens—another hallmark of macrophages. Moreover, genes like CD14 (though not listed here) might be missing, but others like CD74 and CD86 could indicate activated macrophages.\n\nAnother angle: some genes like MS4A6A and MS4A7 are part of the MS4A family, which includes CD20 (MS4A1), commonly found in B-cells, but MS4A6A/7 might have different expression profiles. However, combined with other markers, they might still point towards macrophages.\n\nLooking for exclusion of other cell types: There's no mention of T-cell markers like CD3, CD4, or CD8. Similarly, B-cell markers like CD19 or CD20 aren't prominent here. Neutrophil markers such as CEACAM3 or MPO aren't listed either. Dendritic cell-specific markers like CD1c or CD11c (ITGAX) aren't present either. So ruling out those possibilities, the most likely candidate is macrophages.\n\nAdditionally, genes like VIM (Vimentin) are general mesenchymal markers but can be expressed in macrophages. Also, SELL (L-selectin) is usually associated with lymphocytes but can be downregulated upon activation, possibly in macrophages.\n\nPutting this all together, the combination of MHC class II molecules, lysosomal enzymes, Fc receptors, and other macrophage-associated genes strongly supports that these tumor cells are of macrophage origin. Considering the context of tumor cells, it's likely a tumor-associated macrophage population, which plays a role in immune suppression and promoting cancer progression.\n\nTherefore, after careful analysis, the conclusion aligns with the initial hypothesis.</think>Tumor-associated macrophage",
         "CD14+ Mono"
        ],
        [
         "19",
         "GCACGGACCAGCTA",
         " Now let's tackle this long list step by step.\n\nFirst, I notice several genes related to immune function here. For example, CD3D, CD3G, CD3E are components of the T-cell receptor complex, indicating that these cells may be T-cells. In addition, IL2RA (CD25) is usually associated with activated T-cells or regulatory T-cells (Tregs), but it doesn't appear in the list. However, there are other cytokine-related genes such as IL1B, IL32, and CCL5, which may indicate pro-inflammatory or Th1-type responses.\n\nNext, look at cytotoxicity-related genes. granzymes (GZMM, GZMH) and perforins (PRF1) are typically found in cytotoxic T lymphocytes (CTLs) or natural killer (NK) cells. The presence of these genes suggests that the cells have cytotoxic capabilities, pointing towards effector T cells or NK cells. However, NK cells usually express more specific markers like NCAM1 (CD56) and FCGR3A (CD16), neither of which are present here. Therefore, it is more likely to be an effector T cell.\n\nThen, check for other T-cell subpopulation markers. For example, CD4 is a helper T-cell marker, while CD8 is a cytotoxic T-cell marker. cd8a or cd8b do not appear in the list, whereas cd4 does not either. However, there are other genes such as CD7, CD2, and CD52, which are common markers for T cells. Additionally, SELL (L-selectin) plays a role in initial T-cell homing but may be downregulated upon activation, so its absence does not rule out activated T cells.\n\nOther notable genes include CXCR4, which is involved in T-cell migration and homing, and S100A family members (e.g., S100A9, S100A4), which may be associated with inflammation or specific T-cell subsets. For example, S100A9 (calgranulin B) is commonly found in neutrophils, but some studies suggest its expression in activated T cells under certain conditions.\n\nIn addition, genes like LYZ (lysozyme) and CSTB (cathepsin B) are lysosomal enzymes that may be expressed in activated T cells due to their involvement in antigen presentation or processing. There are also heat shock proteins (HSP90AB1, HSP90B1) and stress response genes, which may reflect the active state of these cells.\n\nTo summarize, key points include:\n\nPresence of CD3 complex genes: confirms T-cell identity.\nExpression of cytotoxic molecules (GZMM, PRF1): indicative of effector T cells (CD8+).\nAbsence of NK-specific markers (e.g., CD56, CD16).\nPresence of activation markers (IL1B, CCL5) and signaling molecules (FOS, JUN).\nConsideration of possible confounding factors (e.g., NK cells excluded due to lack of CD56, CD16).\nTherefore, combining all these factors, the most plausible conclusion is that these are cytotoxic T cells (CD8+). Although the initial hypothesis was CD4+ T cells, further analysis reveals a stronger bias toward cytotoxic functions, thus favoring CD8+ T cells.</think>Cytotoxic CD8+ T cells",
         "Memory CD4 T"
        ],
        [
         "20",
         "GCACTAGAAGATGA",
         " Now let's tackle this problem step by step.\n\nFirstly, the user provided a long list of genes that are said to be highly expressed in a specific type of tumour cell, and needs to determine the cell type based on these markers. The key is to identify which of these genes are known markers for particular immune or other cell types.\n\nStart with the most common B-cell markers: CD79A and CD79B (components of the B-cell receptor complex), MS4A1 (CD20, another classic B-cell marker). These three genes suggest that the tumour cells may originate from B-cells.\n\nNext, look at other genes associated with B-cells. For example, CD19 is also a typical B-cell marker, but it does not appear in the list. However, there are many HLA-related genes such as HLA-DRA, HLA-DRB1, etc., which encode components of MHC class II molecules, indicating that these cells may be antigen-presenting cells, such as B-cells or dendritic cells. But combined with the presence of CD79 family genes, B-cells are more likely.\n\nThen, check for markers related to germinal centre B-cells. For example, BCL6 is an important transcription factor for GC B-cells, but it is not listed here. However, there are genes like LMO2, which may play a role in some cases, but they do not appear either. Instead, there are genes like CD83 (not present) or CD10 (not present), which may indicate different subtypes. However, the presence of CD79A/B and HLA-DR suggests that these cells are activated B-cells rather than naive or memory B-cells.\n\nIn addition, the list includes several interferon-stimulated genes (ISGs): IFI44L, IFI27L2, ISG20, MX1, OAS1, OASL, etc., which may indicate viral infection or chronic activation of the immune system, which is common in tumours such as chronic lymphocytic leukaemia (CLL) or follicular lymphoma.\n\nAlso note the presence of genes like LTB (lymphotoxin beta), which plays a role in the formation and maintenance of germinal centres, although it is not certain whether it is expressed in GC B-cells. In addition, BCL11A may be involved in B-cell development, but further confirmation is needed.\n\nOther possible markers include CD5 (not present), CD23 (not present), and others. There is also CD37 and CD72, which are low affinity IgE receptors found in mature B-cells. In addition, genes like FCGR3A (CD16a) may be expressed in atypical memory B-cells or certain subsets of B-cells, but need to be judged in combination with other markers.\n\nTaken together, the high expression of CD79A/B, MS4A1 (CD20), HLA-DR, along with other B-cell related genes, points towards tumours originating from B-cells. Considering the presence of germinal centre-associated genes (e.g., LTB) and interferon response genes, it may point to a subtype of B-cell lymphoma, such as follicular lymphoma or diffuse large B-cell lymphoma (DLBCL). However, further confirmation is needed to see if there are specific markers for germinal centre B-cells, e.g., CD10, BCL6, but they are absent here. However, the presence of LTB and some ISGs may support the idea of a germinal centre origin.\n\nIn summary, the main markers point to B-cells, while the combination of HLA-DR and LTB may favour a germinal centre phenotype. Therefore, the final annotation should be Germinal centre B cell.</think>Germinal centre B cell",
         "B"
        ],
        [
         "21",
         "GCCACGGATACTGG",
         " First, I need to recall what each gene does and which cell types they're associated with.\n\nS100A9: This is a marker for myeloid cells like neutrophils and monocytes.\nLYZ: Lysozyme, found in macrophages and other myeloid cells.\nCD74: Involved in antigen presentation, common in lymphocytes but also myeloid.\nCCR7: Chemokine receptor involved in lymphocyte homing to lymph nodes.\nHLA-DRA: Part of MHC class II molecules, important for antigen presentation (myeloid).\nLTB: Lymphotoxin beta, produced by activated lymphocytes and some myeloid cells.\nFCN1: Ficolin-1, associated with macrophages.\nIL7R: Interleukin-7 receptor, more in T-cells but can be in some myeloid.\nAIF1: Allograft inflammatory factor 1, seen in macrophages.\nANXA1: Annexin A1, found in various immune cells including neutrophils.\nIFIT2, ISG15: Interferon-induced genes, often in response to viral infection but can be part of baseline in immune cells.\nRGCC: Regulator of G-protein signaling, expressed in many cells.\nVIM: Vimentin, a cytoskeletal protein in mesenchymal cells but also in phagocytes.\nHSPA1A: Heat shock protein, stress response.\nCXCR4: Chemokine receptor involved in cell migration, found in various immune cells.\nCD8B: Part of the CD8 complex, specific to cytotoxic T-cells, but also in NK cells and dendritic cells.\nPLAC8: Placenta-like C-type lectin 8, maybe in dendritic or macrophage?\nFOS: Early response gene, active in many cells upon activation.\nCD52: Found in lymphocytes but also in some myeloid cells.\nCD2: Common in T-cells but also in some myeloid subsets.\nIL32: Interleukin 32, expressed in various leukocytes.\nSELL: L-selectin, initial homing receptor, found on naive lymphocytes.\nGIMAP7: Germinal center-associated gene, possibly B-cell related.\nSAT1: S-adenosyltransferase, involved in metabolism.\nDUSP1: Dual specificity phosphatase, regulating MAP kinases.\nFTL: Ferritin light chain, iron storage.\nCD6: Not typical for T-cells but present in some myeloid cells.\nUCP2: Uncoupling protein 2, energy metabolism.\nTHEMIS: Thrombopoietin embryonic microphthalmia interacting suppressor, maybe hematopoietic.\nBLK: B-cell kinase, definitely B-cells.\nNPC2: Niemann-Pick C2, lysosomal enzyme, found in phagocytes.\nRARRES3: Relaxin-related peptide 3, chemotactic for neutrophils.\nBTG1: Growth control protein, expressed in lymphocytes and fibroblasts.\nSERPINB9: Serpin B9, inhibits proteases, found in various cells.\nCLEC2D: C-type lectin domain family 2 member D, maybe myeloid.\nEMP3: Endoplasmic reticulum membrane protein 3, stress response.\nCYBA: Component of NADPH oxidase, critical for neutrophil function.\nCD55: Decay-accelerating factor, complement regulation.\nCTSH: Cathepsin H, lysosomal protease.\nSKAP1: Sarcoma kinase-associated protein, involved in signaling.\nSH3BGRL3: SH3 domain binding glucose-regulated lipid transfer protein, not sure.\nGAPDH: Glyceraldehyde-3-phosphate dehydrogenase, ubiquitous.\nHSP90AA1: Heat shock protein 90 alpha, stress response.\nPIK3IP1: Phosphoinositide 3-kinase interacting protein 1.\nMALAT1: Metastasis-associated lung adenocarcinoma transcript 1, oncogene.\nTSPYL2: Telomerase-associated protein, expression varies.\nBIN2: BRCA1-interacting nuclear factor 2, DNA repair.\nNDRG1: Neurodevelopmentally derived growth regulator, stress response.\nCEBPB: CCAAT/enhancer-binding protein beta, myeloid differentiation.\nGCSAM: Granulocyte colony stimulating agent modulator, myeloid.\nGMFG: Globular melanoma-fusion glycoprotein, myeloid.\nTMSB4X: Thymosin beta 4 xenopus, cytoskeleton organization.\nEVL: Ena/VASP-like, actin remodeling.\nHSPA5: Heat shock protein 70 kDa alpha 5, stress response.\nP2RY8: Purinergic receptor P2Y-like 8, immune cells.\nPASK: Protein serine/threonine kinase, signaling.\nRPS4Y1: Ribosomal protein S4Y, ribosome structure.\nHSPA8: Heat shock protein 70 kDa alpha 8, stress response.\nLIMD2: LIM domain only 2, cytoskeleton.\nS1PR4: Sphingosine-1-phosphate receptor 4, lymphocyte trafficking.\nLDHB: Lactate dehydrogenase B, metabolic.\nEVIL: Erythrocyte membrane protein 1-like, red blood cells.\nHCLS1: Histone-like chromosome structural protein 1, chromatin.\nHSP90AB1: Heat shock protein 90kDa alpha (maker) variant B1, stress response.\nHLA-B, -C, -A: MHC class I molecules, present in all nucleated cells.\nITGB2-AS1: Integrin beta 2 antisense RNA 1, regulatory.\nHLA-E: Non-classical MHC class I, immune regulation.\nINPP5D: Inositol polyphosphate-5-phosphatase delta, lipid metabolism.\nMEI1: Mitotic exit network 1, cell cycle.\nMIF: Macrophage inflammation protein 1-alpha, cytokine.\nPIK3R5: Phosphoinositide-3-kinase regulatory subunit 5.\nPLEKHB1: Pleckstrin homology domain containing, signal transduction.\nARPC1B: Actin-related protein 2/3-1 beta, cytoskeleton.\nACTB: Beta-actin, cytoskeleton.\nHSP90B1: Heat shock protein 90kDa alpha (maker) variant B1, stress response.\nSORL1: Sortilin-related vesicle sorting protein 1, endosomes.\nTSPYL2: Telomerase-associated protein-like 2.\nBIN2: BRCA1-interacting nuclear factor 2.\nNDRG1: Neural differentiation 1, stress response.\nCEBPB: CCAAT/enhancer-binding protein beta, myeloid.\nGCSAM: Granulocyte colony-stimulating factor modulatory activity.\nGMFG: Globular melanoma-fusion glycoprotein.\nTMSB4X: Thymosin beta 4 xenopus.\nEVL: Ena/VASP-like.\nHSPA5: Heat shock protein 70 kDa alpha 5.\nP2RY8: Purinergic receptor P2Y-like 8.\nPASK: Protein serine/threonine kinase.\nRPS4Y1: Ribosomal protein S4Y.\nHSPA8: Heat shock protein 70 kDa alpha 8.\nLIMD2: LIM domain only 2.\nS1PR4: Sphingosine-1-phosphate receptor 4.\nLDHB: Lactate dehydrogenase B.\nEVIL: Erythrocyte membrane protein 1-like.\nHCLS1: Histone-like chromosome structural protein 1.\nHSP90AB1: Heat shock protein 90kDa alpha (maker) variant B1.\nHLA-B, -C, -A: MHC class I molecules.\nITM2B: Integral membrane module 2B.\nMT-ND1, etc.: Mitochondrial genes, usually not cell-specific.\nMALAT1: Oncogene.\nTMSB10: Thymosin beta 10.\nRAB25: Ras-related protein.\nRPL36A: Ribosomal protein L36A.\nEEF1B2: Elongation factor 1-beta 2.\nGIMAP2: Germinal-center associated, immunoglobulin mu-associated protein 2.\nSEC11C: Sec11 homolog C.\nSEL1L3: Sel1-like protein 3.\nSYCP2: Synaptonemal complex protein 2.\nVAMP8: Vesicle-associated membrane protein 8.\nMT-CYB: Mitochondrial cytochrome b.\nNPM1: Nuclear pore protein 1.\nALDOA: Aldolase A.\nRBM38: RNA binding motif protein 38.\nZFAS1: Zinc finger antisense RNA 1.\nAPP: Amyloid precursor protein.\nCD81: Tetraspanin 1, involved in immune complexes.\nHMGB1: High mobility group box 1, chromatin.\nPFN1: Polymerase fingerprinting 1.\nCELF2: CelF-like transcription factor 2.\nTNFAIP8: Tumor necrosis factor alpha induced protein 8.\nMAP4K1: Mitogen-activated protein kinase kinase kinase kinase 1.\nPNRC1: Proline-rich circularly permuted 1.\nMT-ATP6: Mitochondrial ATP synthase.\nPSMB9: Proteasome beta 9 subunit.\nITM2B: Integral membrane module 2B.\nRPS26: Ribosomal protein S26.\nTMSB10: Thymosin beta 10.\nRAB25: Ras-related protein.\nRPL36A: Ribosomal protein L36A.\nEEF1B2: Elongation factor 1-beta 2.\nGIMAP2: Germinal-center associated, immunoglobulin mu-associated protein 2.\nSEC11C: Sec11 homolog C.\nSEL1L3: Sel1-like protein 3.\nSYCP2: Synaptonemal complex protein 2.\nVAMP8: Vesicle-associated membrane protein 8.\nMT-CYB: Mitochondrial cytochrome b.\nNPM1: Nuclear pore protein 1.\nALDOA: Aldolase A.\nRBM38: RNA binding motif protein 38.\nZFAS1: Zinc finger antisense RNA 1.\nAPP: Amyloid precursor protein.\nCD81: Tetraspanin 1.\nHMGB1: High mobility group box 1.\nPFN1: Polymerase fingerprinting 1.\nCELF2: CelF-like transcription factor 2.\nTNFAIP8: Tumor necrosis factor alpha induced protein 8.\nMAP4K1: Mitogen-activated protein kinase kinase kinase kinase 1.\nPNRC1: Proline-rich circularly permuted 1.\nMT-ATP6: Mitochondrial ATP synthase.\nPSMB9: Proteasome beta 9 subunit.\nITM2B: Integral membrane module 2B.\nRPS26: Ribosomal protein S26.\nTMSB10: Thymosin beta 10.\nRAB25: Ras-related protein.\nRPL36A: Ribosomal protein L36A.\nEEF1B2: Elongation factor 1-beta 2.\nGIMAP2: Germinal-center associated, immunoglobulin mu-associated protein 2.\nSEC11C: Sec11 homolog C.\nSEL1L3: Sel1-like protein 3.\nSYCP2: Synaptonemal complex protein 2.\nVAMP8: Vesicle-associated membrane protein 8.\nMT-CYB: Mitochondrial cytochrome b.\nNPM1: Nuclear pore protein 1.\nALDOA: Aldolase A.\nRBM38: RNA binding motif protein 38.\nZFAS1: Zinc finger antisense RNA 1.\nAPP: Amyloid precursor protein.\nCD81: Tetraspanin 1.\nHMGB1: High mobility group box 1.\nPFN1: Polymerase fingerprinting 1.\nCELF2: CelF-like transcription factor 2.\nTNFAIP8: Tumor necrosis factor alpha induced protein 8.\nMAP4K1: Mitogen-activated protein kinase kinase kinase kinase 1.\nPNRC1: Proline-rich circularly permuted 1.\nMT-ATP6: Mitochondrial ATP synthase.\nPSMB9: Proteasome beta 9 subunit.\nITM2B: Integral membrane module 2B.\nRPS26: Ribosomal protein S26.\nTMSB10: Thymosin beta 10.\nRAB25: Ras-related protein.\nRPL36A: Ribosomal protein L36A.\nEEF1B2: Elongation factor 1-beta 2.\nGIMAP2: Germinal-center associated, immunoglobulin mu-associated protein 2.\nSEC11C: Sec11 homolog C.\nSEL1L3: Sel1-like protein 3.\nSYCP2: Synaptonemal complex protein 2.\nVAMP8: Vesicle-associated membrane protein 8.\nMT-CYB: Mitochondrial cytochrome b.\nNPM1: Nuclear pore protein 1.\nALDOA: Aldolase A.\nRBM38: RNA binding motif protein 38.\nZFAS1: Zinc finger antisense RNA 1.\nAPP: Amyloid precursor protein.\nCD81: Tetraspanin 1.\nHMGB1: High mobility group box 1.\nPFN1: Polymerase fingerprinting 1.\nCELF2: CelF-like transcription factor 2.\nTNFAIP8: Tumor necrosis factor alpha induced protein 8.\nMAP4K1: Mitogen-activated protein kinase kinase kinase kinase 1.\nPNRC1: Proline-rich circularly permuted 1.\nMT-ATP6: Mitochondrial ATP synthase.\nPSMB9: Proteasome beta 9 subunit.\nITM2B: Integral membrane module 2B.\nRPS26: Ribosomal protein S26.\nTMSB10: Thymosin beta 10.\nRAB25: Ras-related protein.\nRPL36A: Ribosomal protein L36A.\nEEF1B2: Elongation factor 1-beta 2.\nGIMAP2: Germinal-center associated, immunoglobulin mu-associated protein 2.\nSEC11C: Sec11 homolog C.\nSEL1L3: Sel1-like protein 3.\nSYCP2: Synaptonemal complex protein 2.\nVAMP8: Vesicle-associated membrane protein 8.\nMT-CYB: Mitochondrial cytochrome b.\nNPM1: Nuclear pore protein 1.\nALDOA: Aldolase A.\nRBM38: RNA binding motif protein 38.\nZFAS1: Zinc finger antisense RNA 1.\nAPP: Amyloid precursor protein.\nCD81: Tetraspanin 1.\nHMGB1: High mobility group box 1.\nPFN1: Polymerase fingerprinting 1.\nCELF2: CelF-like transcription factor 2.\nTNFAIP8: Tumor necrosis factor alpha induced protein 8.\nMAP4K1: Mitogen-activated protein kinase kinase kinase kinase 1.\nPNRC1: Proline-rich circularly permuted 1.\nMT-ATP6: Mitochondrial ATP synthase.\nPSMB9: Proteasome beta 9 subunit.\nITM2B: Integral membrane module 2B.\nRPS26: Ribosomal protein S26.\nTMSB10: Thymosin beta 10.\nRAB25: Ras-related protein.\nRPL36A: Ribosomal protein L36A.\nEEF1B2: Elongation factor 1-beta 2.\nGIMAP2: Germinal-center associated, immunoglobulin mu-associated protein 2.\nSEC11C: Sec11 homolog C.\nSEL1L3: Sel1-like protein 3.\nSYCP2: Synaptonemal complex protein 2.\nVAMP8: Vesicle-associated membrane protein 8.\nMT-CYB: Mitochondrial cytochrome b.\nNPM1: Nuclear pore protein 1.\nALDOA: Aldolase A.\nRBM38: RNA binding motif protein 38.\nZFAS1: Zinc finger antisense RNA 1.\nAPP: Amyloid precursor protein.\nCD81: Tetraspanin 1.\nHMGB1: High mobility group box 1.\nPFN1: Polymerase fingerprinting 1.\nCELF2: CelF-like transcription factor 2.\nTNFAIP8: Tumor necrosis factor alpha induced protein 8.\nMAP4K1: Mitogen-activated protein kinase kinase kinase kinase 1.\nPNRC1: Proline-rich circularly permuted 1.\nMT-ATP6: Mitochondrial ATP synthase.\nPSMB9: Proteasome beta 9 subunit.\nITM2B: Integral membrane module 2B.\nRPS26: Ribosomal protein S26.\nTMSB10: Thymosin beta 10.\nRAB25: Ras-related protein.\nRPL36A: Ribosomal protein L36A.\nEEF1B2: Elongation factor 1-beta 2.\nGIMAP2: Germinal-center associated, immunoglobulin mu-associated protein 2.\nSEC11C: Sec11 homolog C.\nSEL1L3: Sel1-like protein 3.\nSYCP2: Synaptonemal complex protein 2.\nVAMP8: Vesicle-associated membrane protein 8.\nMT-CYB: Mitochondrial cytochrome b.\nNPM1: Nuclear pore protein 1.\nALDOA: Aldolase A.\nRBM38: RNA binding motif protein 38.\nZFAS1: Zinc finger antisense RNA 1.\nAPP: Amyloid precursor protein.\nCD81: Tetraspanin 1.\nHMGB1: High mobility group box 1.\nPFN1: Polymerase fingerprinting 1.\nCELF2: CelF-like transcription factor 2.\nTNFAIP8: Tumor necrosis factor alpha induced protein 8.\nMAP4K1: Mitogen-activated protein kinase kinase kinase kinase 1.\nPNRC1: Proline-rich circularly permuted 1.\nMT-ATP6: Mitochondrial ATP synthase.\nPSMB9: Proteasome beta 9 subunit.\nITM2B: Integral membrane module 2B.\nRPS26: Ribosomal protein S26.\nTMSB10: Thymosin beta 10.\nRAB25: Ras-related protein.\nRPL36A: Ribosomal protein L36",
         "Naive CD4 T"
        ],
        [
         "22",
         "GCGTAATGCACCAA",
         " Now let's tackle this long list of genes.\n\nFirst, I'll start by looking for key markers. CD68 is a classic macrophage marker, but it's present here. Then there's LYZ (lysozyme), which is also associated with myeloid cells like monocytes and macrophages. HLA-DRA and other HLA class II genes suggest antigen-presenting cells, which macrophages and dendritic cells are. FCGR3A (CD16) is found in NK cells and some macrophage subsets. MS4A family genes (like MS4A6A, MS4A7) are involved in phagocytosis and are expressed in macrophages. CST3 (cystatin C) is another macrophage-related gene.\n\nLooking further, genes like AIF1 (allograft inflammatory factor 1) and TYROBP are indicative of myeloid lineage cells. S100A proteins (S100A9, S100A4, etc.) are often seen in neutrophils and macrophages during inflammation. SPI1 (PU.1) is a transcription factor critical for myeloid development. Genes like FCGRT and FCGRT are part of the Fc receptor complex, important in immune cells.\n\nThere's also FCER1G, which is part of the IgE receptor and found in various myeloid cells. CD74 and HLA-DR genes reinforce the antigen presentation angle. The presence of multiple lysosomal enzymes (CTSB, CTSS, CTSZ) points towards active phagocytosis, typical of macrophages. Additionally, genes like CD14 or CD68 support this.\n\nSome genes like CD37 and CD79B might be confusing because they're usually B-cell markers, but maybe cross-checked against other markers. However, given the overall context, the majority of these genes align more with macrophage functions rather than B-cells.\n\nPutting this all together: the combination of classical macrophage markers (CD68, LYZ), myeloid-specific genes (SPI1, FCGR3A), antigen presentation genes (HLA-DR), and lysosomal enzymes strongly suggests that these tumor cells are of macrophage origin. Therefore, the correct annotation would be Macrophage.</think>Macrophage",
         "FCGR3A+ Mono"
        ],
        [
         "23",
         "GGACCGTGGGAACG",
         " Now let's tackle this long list step by step.\n\nFirst, look at the gene names provided. I notice several HLA class II genes like HLA-DRA, HLA-DRB1, HLA-DPA1, etc., which are typically associated with antigen-presenting cells (APCs) because they present antigens to T cells via MHC class II molecules. This suggests that the cell type is involved in immune responses and might be part of the immune system.\n\nNext, there are many genes related to lysosomes or phagocytosis, such as FCER1G, FCGR2A, FCGR1A, and FCER1A. These genes are involved in immune receptor signaling and are commonly found in myeloid cells like monocytes, macrophages, dendritic cells, etc. The presence of multiple FCGRs (Fc gamma receptors) points towards phagocytic cells.\n\nThen, there are some markers for specific immune cells. For example, CD74 is involved in MHC class II antigen presentation, again supporting APCs. CD1 family members like CD1C and CD1E are also present here, which are specialized in presenting lipids and are often found in dendritic cells. CD68 is a classic macrophage marker, but it can also be expressed in other myeloid cells. LYZ encodes lysozyme, an enzyme produced by macrophages and neutrophils. CST3 (cystatin C) is another macrophage-associated gene.\n\nLooking further, there are several S100 proteins: S100A8, S100A9, S100A4, etc. These are often co-expressed in neutrophils and monocytes/macrophages during inflammation. However, their presence doesn't necessarily distinguish between these cell types.\n\nOther notable genes include AIF1 (allograft inflammatory factor 1), which is expressed in macrophages. TYROBP is a signaling molecule involved in natural killer cell and myeloid cell activation. TREM1 is a trigger-related expression module 1, associated with granulocyte-macrophage progenitor cells and activated monocytes/macrophages.\n\nThere's also CD48, which is involved in cell-cell interactions and is expressed on various leukocytes, including monocytes and macrophages. Additionally, genes like FPR1 (formyl peptide receptor 1) are expressed in neutrophils and monocytes.\n\nNow, considering the combination of HLA class II genes, lysosomal/antigen-presenting genes (FCER1G, CD74), CD1 family members (CD1C, CD1E), and macrophage/microglial markers (LYZ, CD68, AIF1), along with some S100 proteins and TREM1, this seems to point towards a cell type that has both antigen-presenting capabilities (like dendritic cells) and phagocytic functions (like macrophages). Monocytes, upon differentiation into macrophages or dendritic cells, would express these markers. However, given the presence of CD1C and CD1E, which are more specific to certain dendritic cell subsets, combined with other markers, it might lean more towards dendritic cells.\n\nAnother angle: microglia are a type of macrophage derived from the myeloid lineage and reside in the central nervous system. They share markers with macrophages but have some distinct features. Genes like CSPG4 (NG2), CD44, and C1QTNF3 are common microglial markers, but I don't see those here. Instead, there's more emphasis on antigen presentation and phagocytosis. Also, genes like SPP1 (osteopontin) are associated with microglia, but not listed here.\n\nGiven the abundance of HLA class II genes, CD1 series, and lysosomal enzymes, alongside macrophage markers, but without strong indicators of dendritic cell-specific markers (like CLEC9A for conventional dendritic cells or CD11c for cDC1/cDC2), it's possible that the cell type is a dendritic cell. Alternatively, if the markers overlap significantly with macrophages, then maybe it's a monocyte-derived macrophage. However, the presence of CD1C and CD1E complicates things since these are typically found in certain dendritic cell subpopulations.\n\nMoreover, genes like CLEC10A (CD301) are found on classical dendritic cells. Also, IRF8 is a key transcription factor for dendritic cells, but I don't see IRF8 in the list. However, other genes like TYROBP and TREM1 are involved in dendritic cell activation.\n\nIn summary, the combination of HLA class II, CD1 family, lysosomal genes, and macrophage markers could indicate either dendritic cells or macrophages. Considering the presence of CD1C and CD1E, which are more specific to certain dendritic cell subsets, along with other markers like CLEC10A and TYROBP, it's likely that the cell type belongs to the dendritic cell lineage. Therefore, after evaluating all these factors, the most probable answer is dendritic cell.</think>Dendritic cell",
         "DC"
        ],
        [
         "24",
         "GGACCTCTGTAAGA",
         " Now let's tackle this long list step by step.\n\nFirst, look at some key genes in the list. For example, CD14 is usually associated with monocytes or macrophages because it's a marker for these immune cells. Then there's LYZ (lysozyme), which is also found in myeloid cells like neutrophils and monocytes. HLA-DRA and other HLA genes (like HLA-DRB1, HLA-DPA1, etc.) are involved in antigen presentation, so that might point to dendritic cells or macrophages since they present antigens.\n\nNext, see if there are any markers specific to monocytes. CD14 again comes up, but wait, there's also MS4A6A and MS4A7. These are part of the MS4A family, which includes CD20 (MS4A1) in B-cells, but MS4A6A and MS4A7 are more linked to monocytes and macrophages. Other genes like FCGR3A (CD16a) can be found in both monocytes and NK cells, but combined with others might help differentiate.\n\nLooking further, there's S100A8 and S100A9. These are calprotectin subunits often seen in neutrophils and monocytes during inflammation. But again, not exclusive. Genes like TYROBP and CST3 are also associated with myeloid cells. SPI1 (PU.1) is a transcription factor critical for myeloid development, including monocytes.\n\nThere's also FCER1G, which is part of the Fc receptor complex, common in various immune cells. However, the presence of multiple HLA class II genes suggests antigen-presenting cells, which fits monocytes/macrophages or dendritic cells. But without more specific markers, maybe monocytes?\n\nWait, but there's also CD74, which is involved in MHC class II antigen presentation, again pointing to antigen-presenting cells. And genes like SELL (L-selectin) are involved in lymphocyte homing, but monocytes can express it too.\n\nAnother angle: check for absence of exclusivity. For example, if the list had CD3 or CD19, that would rule out T or B cells. The lack of those along with the mentioned genes supports myeloid lineage. Also, genes like AIF1 (Allograft inflammatory factor 1) are expressed in macrophages.\n\nPutting this together, the combination of CD14, HLA-DR genes, S100 proteins, and other myeloid-related genes points towards monocytes. Since the question specifies tumor cells, perhaps a monocytic leukemia or sarcoma with monocytic differentiation? Alternatively, tumor-associated macrophages could be considered, but the initial query mentions tumor cells, possibly referring to the cell type within the tumor microenvironment rather than the tumor itself being of monocytic origin.\n\nFinal answer: Monocyte</think>Monocyte",
         "CD14+ Mono"
        ],
        [
         "25",
         "GGCCGAACGCAGAG",
         " Now I need to analyze the user-provided gene list to determine the tumor cell types in which these genes are highly expressed.\n\nFirst, I will review some common markers for different immune cells:\n\nCD3D: T-cell specific marker.\nIL7R: Common to memory T-cells, especially CD4+ T-cells.\nCD2: General T-cell marker.\nCD27: Marker for memory T-cells and plasma cells.\nTCERG1 (not listed here): May be associated with activated T-cells.\nCXCR4: Involved in homing of lymphocytes, including memory T-cells.\nSELL (CD62L): Homing receptor, usually found in central memory T-cells.\nCD45RA vs. CD45RO: Not mentioned here, but other markers may compensate.\nFOS/JUN: Early response genes that may indicate activation.\nGZMB: Granzyme B is present in cytotoxic T-cells but not listed here.\nCD8: Not explicitly mentioned, but it may be inferred from other markers.\nNext, check if there are any markers characteristic of other cell types:\n\nNK cell markers such as NCAM1 (CD56) or CD16 (FCGR3A) were not evident.\nB cell markers like CD19 or CD20 (MS4A1) were also absent.\nMonocyte/macrophage markers such as CD14 or CD68 were not prominent.\nStalk-like markers such as CD5 (in NK cells) or CD11b (ITGAM) were not obvious.\nThen consider possible combinations of genes:\n\nHigh expression of CD3D indicates T-cell origin.\nIL7R and CD27 point towards memory T-cells.\nSELL suggests central memory T-cells.\nCXCR4 plays a role in lymphocyte migration and may be involved in homeostasis.\nGenes like FOS and JUN might reflect an activated state.\nThere was no mention of CD8A or CD8B, so it could be CD4+ memory T-cells.\nAlso, check for potential confounding factors:\n\nAre there markers for effector memory T-cells? For example, CD45RO (not listed), but possibly other markers.\nAre there markers for regulatory T-cells (Tregs)? For example, FOXP3 (not listed here).\nHowever, the presence of IL7R and CD27 favors conventional memory T-cells rather than Tregs.\nIn addition, check for possible contaminants or cross-expression:\n\nFor example, can CD4+ T-cells express some CD8-related genes?\nBut generally, CD4+ T-cells do not typically express high levels of CD8 unless they undergo differentiation into cytotoxic T-cells, which seems unlikely given the absence of granzymes.\nTherefore, taking all this into account, the most likely conclusion is that these genes are highly expressed in CD4+ memory T-cells.</think>CD4",
         "Naive CD4 T"
        ],
        [
         "26",
         "GGGAACGAAGCTCA",
         " First, I need to carefully read through the user-provided gene list to identify any key markers that might indicate specific immune cell types.\n\nFirstly, I notice several lysosomal enzyme-related genes such as CTSD (Cathepsin D), CTSL (Cathepsin L), and CTSZ (Cathepsin Z). These enzymes are commonly found in antigen-presenting cells like macrophages or dendritic cells because they process antigens for presentation via MHC class II molecules.\n\nNext, there are multiple HLA genes: HLA-DRA, HLA-DRB1, HLA-DPA1, HLA-DQB1, HLA-DQA1, HLA-DPB1, etc., which encode components of MHC class II molecules. Macrophages, especially when activated, express high levels of MHC class II molecules, facilitating antigen presentation to T cells.\n\nThen, there is CD74, an invariant chain involved in MHC class II formation, further supporting the presence of antigen-presenting cells. Additionally, FCGR3A (CD16a) and FCER1G may suggest myeloid lineage cells, possibly monocytes or macrophages.\n\nLYZ (Lysozyme) and AIF1 (Allograft inflammatory factor 1) are also indicative of myeloid cells. The presence of genes like S100A family members (S100A9, S100A4, etc.) can be associated with various immune cells, including neutrophils and macrophages, but combined with other markers, they may point more towards macrophages.\n\nOther notable genes include TYROBP (DAP12), which interacts with signaling receptors in myeloid cells, and MNDA (Myeloid cell nuclear differentiation antigen), both strongly suggesting myeloid origin.\n\nLooking at some other markers: CD68 is a classic macrophage marker, though it's not listed here. However, other lysosomal enzymes and MHC II genes make up for this absence. Also, genes like C1QA and C1QB belong to the complement system, often produced by macrophages and microglia.\n\nAdditionally, genes like FCGRT (Fc gamma receptor) and FCGR2A are involved in antibody-mediated phagocytosis, common in macrophages. The presence of CSF1R (Macrophage colony-stimulating factor 1 receptor) is another strong indicator of macrophages.\n\nPutting all these together—antigen presentation-related genes (HLA class II), lysosomal enzymes, myeloid-specific markers (FCGRs, CSF1R)—the most likely cell type is macrophages. Considering the context of tumor cells, this could refer to tumor-associated macrophages (TAMs), which play significant roles in cancer progression and immune suppression.</think>Tumor-associated macrophages",
         "FCGR3A+ Mono"
        ],
        [
         "27",
         "GTAGTGTGAGGCGA",
         " Now let's tackle this step by step.\n\nFirst, I'll scan through the list for any obvious markers. CD68 and LYZ stand out as classic macrophage markers. Then there's HLA-DRA and other HLA genes (HLA-DRB1, HLA-DPB1), which relate to antigen presentation, something macrophages do. S100 proteins like S100A8, S100A9, S100A4, etc., are also associated with myeloid cells and inflammation.\n\nLooking further, genes like FCER1G, TYROBP, and CST3 are involved in immune responses and are found in myeloid lineage cells. There's also FCN1 (ficolin-1), which is expressed in monocytes/macrophages. Genes like AIF1 (allograft inflammatory factor 1) and MARCO (myeloid antimicrobial玫瑰十字架蛋白) are also linked to macrophages.\n\nSome activation markers like CD14 might be missing, but the presence of others compensates. The presence of SPI1 (PU.1) is crucial because it's a transcription factor driving myeloid differentiation. Also, genes like CD48 and CD37 might indicate interaction with other immune cells, common in macrophage environments.\n\nThe absence of dendritic cell-specific markers like CD1c or plasma cell markers like CD38 suggests it's not those lineages. The mitochondrial genes (MT-...) suggest active metabolism, typical of phagocytic cells like macrophages.\n\nPutting this all together, the markers strongly point towards a myeloid origin, specifically macrophages. The combination of lysosomal enzymes (CTSS, CTSH), cytokines (IL10), and immune-related genes fits with activated macrophages in tumors, such as tumor-associated macrophages (TAMs). Therefore, the cell type here is Macrophage.</think>Macrophage",
         "CD14+ Mono"
        ],
        [
         "28",
         "TATAAGTGACACCA",
         " Now I need to analyze these marker genes step by step.\n\nFirstly, I noticed that there were many genes related to antigen presentation in the list, such as HLA-DRA, HLA-DRB1, HLA-DPA1, HLA-DPB1, etc., which belong to MHC class II molecules and may be associated with antigen-presenting cells (e.g., dendritic cells, macrophages). In addition, CD74 is an important chaperone protein for MHC class II molecules, further supporting this direction.\n\nNext, look at other possible markers. For example, CD14 is usually found in monocytes/macrophages, while CD68 and CD163 are common markers for macrophages. However, it should be noted that CD163 does not appear in the list, but CD68 appears, which may point to tissue-specific macrophage subpopulations. In addition, LYZ (lysozyme) is commonly seen in myeloid cells, including neutrophils and monocytes, although it may also be expressed in macrophages.\n\nThen, there are several lysosomal enzyme-related genes, such as CTSS, CTSL, CTSB, and CTSZ, which are involved in phagocytosis and degradation of pathogens or cellular debris, typical features of macrophages. There are also genes like FCGR3A (CD16), which may suggest a subset of macrophages or NK cells, but combined with other markers, it may indicate non-classical monocyte-derived macrophages.\n\nIn addition, some interferon-stimulated genes (ISGs) such as IFIT3, IFI30, and MX1 do appear, suggesting activation status, possibly due to chronic inflammation or infection, which is consistent with the characteristics of tumor-associated macrophages (TAMs).\n\nNow, let's rule out other possibilities. For example, dendritic cells may express CD1c, CD11c, etc., but they don't seem to appear here. Neutrophil markers such as CEACAM8, MPO, etc., are absent as well. Monocytes themselves may express CD14, CD16 (FCGR3A), CD74, etc., but upon differentiation into macrophages, specific markers will emerge. Therefore, considering the combination of antigen presentation-related genes, lysosomal enzymes, and exclusion of other immune cell types, it is more likely that these cells are monocyte-derived macrophages, especially in the context of tumors where TAMs play a role.</think>Monocyte",
         "FCGR3A+ Mono"
        ],
        [
         "29",
         "TGGACCCTACACTG",
         " Now let's tackle this problem step by step.\n\nFirstly, I need to carefully read through the list of genes provided by the user. The task is to determine which tumour cell types these genes are most likely associated with based on their high expression levels.\n\nNext, I will start by identifying some key genes from the list that are known markers for specific immune cells or other cell types. For example:\n\nS100A8 and S100A9: These two genes form calprotectin, which is commonly found in myeloid cells such as neutrophils and monocytes.\nCD14: This gene encodes a receptor for lipopolysaccharide (LPS) and is typically expressed in monocytes/macrophages.\nLYZ (Lysozyme): An enzyme produced by macrophages and monocytes involved in breaking down bacterial cell walls.\nFCER1G: Part of the Fc epsilon receptor complex, often seen in myeloid cells like mast cells and monocytes.\nHLA-DRA and HLA-DRB1: MHC class II molecules, indicating antigen-presenting cells such as dendritic cells, B cells, or macrophages.\nTYROBP: Involved in signalling in natural killer cells and myeloid cells.\nFCN1 (Ficolin-1): Associated with monocyte subsets and complement activation.\nANXA1 (Annexin A1): May be expressed in various immune cells, including monocytes.\nVIM (Vimentin): A cytoskeletal protein present in mesenchymal cells, but also in activated monocytes.\nADM (Adrenomedullin): Can be secreted by monocytes under inflammatory conditions.\nS100A4 and S100A6: Members of the S100 family, possibly related to inflammation and monocyte function.\nCD300E: An inhibitory receptor on monocytes and regulatory T cells.\nCD74: Again part of MHC class II complexes.\nOther genes like CST3 (Cystatin C), LYZ, and FCN1 reinforce the presence of monocytes or macrophages. Additionally, genes such as AIF1 (Allograft inflammatory factor 1) are expressed in macrophages.\n\nNow, considering possible tumour-associated scenarios, these genes might indicate a monocytic origin. Monocytic leukaemias, such as acute monocytic leukaemia (AML-M5), characteristically express many of these markers. Moreover, chronic myelomonocytic leukaemia (CMML) could also fit here. In addition, certain lymphomas may have monocytic differentiation features.\n\nHowever, it's important to rule out other possibilities. For instance, dendritic cells would share some MHC class II genes, but the presence of S100A8/A9 and CD14 leans more towards monocytes. Macrophage markers overlap significantly, so distinguishing between them can be challenging. However, given the combination of both myeloid (S100 proteins, CD14) and lymphoid (HLA-DR) markers, a monocytic lineage is plausible.\n\nIn summary, the high expression of these genes strongly suggests a monocytic cell type. Considering the tumour context, the most likely diagnosis is monocytic leukaemia or a related disorder. Therefore, after careful analysis, the answer should be monocytic.</think>Monocytic",
         "CD14+ Mono"
        ],
        [
         "30",
         "TTAGTCTGTGCACA",
         " First, I need to identify which of these genes are known markers for specific immune cells.\n\nStart by looking at some of the listed genes:\n\nLYZ: Lysozyme, often found in myeloid cells like macrophages.\nCD74: Involved in antigen presentation, common in antigen-presenting cells (APCs) such as dendritic cells and macrophages.\nGZMA: Granzyme A, associated with cytotoxic cells but also present in some activated macrophages.\nLTB: Lymphotoxin beta, involved in inflammation and produced by various immune cells including macrophages.\nANXA1: Annexin A1, seen in monocytes and macrophages.\nCST7: Cystatin F, expressed in lymphocytes and macrophages.\nLGALS1: Lectin-like oxidized LDL receptor 1, linked to macrophage function.\nISG15: Interferon-stimulated gene 15, can be upregulated in macrophages during infection.\nVIM: Vimentin, a cytoskeletal protein found in many cells, including macrophages.\nCXCR4: Chemokine receptor, involved in monocyte migration.\nS100A4: Part of the S100 family, associated with macrophages and other myeloid cells.\nFOS/JUN: Early response genes, widely expressed upon activation.\nCD52: Found on lymphocytes and some myeloid cells.\nCD3D/CD3E: T-cell markers, but their presence here might indicate contamination or specific subsets.\nIL32: Secreted by activated T cells and macrophages.\nITGB2: Integrin beta 2, part of the Mac-1 marker, typical of monocytes/macrophages.\nS100A6/A10/A4: Members of the S100 calcium-binding protein family, commonly expressed in myeloid cells.\nFTL/FTL1: Ferritin light chain, involved in iron storage, high in macrophages.\nLAPTM5: Lemur tyrosine phosphatase, expressed in lymphocytes and macrophages.\nTRAT1: Transcription regulator, may play roles in macrophage functions.\nHCST: Heat shock cognate 70 kDa protein, expressed in various cells.\nCD22: Typically B-cell marker, but possible in certain contexts.\nCD53: Broadly expressed on leukocytes, including macrophages.\nCD48: Interaction molecule, present on various immune cells.\nIFITM1/2: Interferon-induced transmembrane proteins, found in macrophages.\nMX1: Myxovirus resistance protein, induced by interferons, present in macrophages.\nTAGAP: T-cell activation gene-associated protein, possibly in macrophages.\nRHOH: Ras homolog family member H, active in macrophages.\nCD44: Adhesion molecule, involved in cell migration, highly expressed in memory T-cells and macrophages.\nKLF2/KLF6: Kruppel-like factors, involved in macrophage development.\nFCGR2A/B/C: Not listed, but FC receptors are common in phagocytes.\nCD68: Typical macrophage marker, not listed here.\nCD14: Monocyte marker, not listed either.\nCD163: Macrophage marker, absent here.\nCD11b/ITGAX: Not explicitly mentioned, but ITGB2 is present.\nOther genes:\nMALAT1: Long non-coding RNA, broadly expressed.\nACTB/GAPDH/HSPA genes: Housekeeping genes, not specific.\nHLA genes (HLA-A, -B, -C): Present in all nucleated cells, including APCs.\nNow, consider the absence of key markers for other cell types:\n\nT cells: Lack CD3D/E, except for some cases where CD3 might be co-expressed in certain subpopulations.\nB cells: Absence of CD19, CD20, CD79a/b.\nNK cells: No CD56 (NCAM1), no NKG2D.\nDendritic cells: Lack CD1c, CD11c (ITGAX).\nNeutrophils: No CEACAM8, ELANE.\nThe presence of multiple lysosomal enzymes (CTSB, CTSG), scavenger receptors, and chemokines (CXCR4) supports a myeloid lineage. Additionally, genes like S100A family members, FTL, and LAPTM5 are more indicative of macrophages rather than dendritic cells or neutrophils.\n\nMonocyte/macrophage markers include CD14 (not listed), CD163 (not listed), CD68 (not listed), but given the list, there's overlap with some macrophage markers. However, since CD68 isn't present, but others like LYZ, CD74, CST7, etc., are, it leans towards macrophages. Also, monocytes share some markers with macrophages, especially when differentiated.\n\nPossible confounding factors:\n\nPresence of some T-cell related genes (CD3D/E, CD5, CD44) could suggest mixed populations or different states. However, considering the overall profile, the majority of markers point towards myeloid lineage.\nSome genes like CD52 are shared between lymphocytes and macrophages, so this isn't conclusive.\nIn conclusion, despite some T-cell related genes, the combination of multiple macrophage-specific markers (LYZ, CD74, CST7, LGALS1, etc.) strongly suggests that the tumor cells belong to a macrophage subtype within the myeloid lineage.</think>Macrophage",
         "Memory CD4 T"
        ],
        [
         "31",
         "TTATGGCTTATGGC",
         " Now let's tackle this long list of genes.\n\nFirst, I notice several HLA genes: HLA-DRA, HLA-DRB1, HLA-DPA1, HLA-DQB1, etc. These are part of the major histocompatibility complex (MHC) class II molecules, which are typically expressed in antigen-presenting cells like dendritic cells, macrophages, and B cells. That's a clue pointing towards immune cells involved in presenting antigens.\n\nThen there are genes like CD74, which is involved in MHC class II antigen presentation, and CD83, a marker for activated dendritic cells. There's also FCER1G and FCER1A, which are part of the Fc epsilon receptor, often found in myeloid cells such as mast cells or dendritic cells. The presence of CCR7 suggests chemotaxis towards lymph nodes, which dendritic cells use to migrate after capturing antigens.\n\nLooking further, there's LYZ (lysozyme), which is common in myeloid cells like neutrophils and monocytes. CD68 and CD14 aren't listed here, but CD68 is present. Also, genes like AIF1 (allograft inflammatory factor 1) are associated with macrophage activation. TYROBP is a signaling molecule in myeloid cells, particularly in natural killer cells and dendritic cells.\n\nSome other markers include CLEC10A (a C-type lectin involved in pathogen recognition), FCGR2A (Fc gamma receptor), and ITGAX (CD11c), though ITGAX isn't listed here. However, CD1C and CD1E are CD1 family members, which are presented by professional antigen-presenting cells like dendritic cells.\n\nThere are also genes related to antigen processing and presentation, such as TAP1, which isn't listed, but other MHC-related genes are present. Genes like CCL5 (chemokine ligand 5) can be produced by activated macrophages and dendritic cells.\n\nConsidering the combination of MHC class II genes, antigen presentation-related proteins (like CD74), and various myeloid markers (LYZ, CD68, TYROBP), along with some specific dendritic cell markers (FCER1A, CLEC10A), this seems to point towards a myeloid lineage with antigen-presenting capabilities. Given that dendritic cells are professional antigen-presenting cells, especially when activated, the presence of activation markers like CD83 and chemokine receptors like CCR7 supports this.\n\nAdditionally, some genes like S100A4 and S100A6 are calcium-binding proteins expressed in activated leukocytes, including dendritic cells. The absence of T-cell markers (like CD3D/CD3E) and B-cell markers (like CD19/CD20) further narrows it down.\n\nPutting this all together, the most likely cell type here is dendritic cells, specifically a subtype that might be activated or mature, given the presence of activation markers and antigen presentation genes.</think>Mature dendritic cell",
         "DC"
        ],
        [
         "32",
         "TTCAGACTCTCGAA",
         " First, I need to recall what each gene does and which cell types they're associated with.\n\nStarting with the list: MS4A6A is involved in antigen presentation, so maybe immune cells? LYZ is lysozyme, found in macrophages and neutrophils. CCR7 is a chemokine receptor for lymphocyte homing. KLRB1 (CD161) is in NK cells and dendritic cells. IL7R is common in T cells. CD69 is an early activation marker for T cells. DUSP2 is involved in T-cell signaling. RGS1 regulates T-cell migration. ALOX5AP is part of leukotriene synthesis. ANXA1 is in various immune cells. SPON2 might be less known. RGCC is related to cell proliferation. VIM is vimentin, a mesenchymal marker but also in some immune cells. CXCR4 is a chemokine receptor in memory T cells. S100A4 is associated with activated T cells. CD8B is part of the CD8 complex in cytotoxic T cells. PLAC8 is in plasma membranes. FOS and JUN are immediate early genes in many cells. CD52 is present in lymphocytes. CD2 and CD3D are T-cell markers. IL32 is secreted by activated T cells. SELL (CD62L) is a homing receptor. GIMAP7 is in lymphocytes. DUSP1 is again T-cell related. FTL is ferritin light chain. KLRF1 is in NK cells. S100A10 is in myeloid cells. LAPTM5 is in lymphocytes. TUBA1B is tubulin. ZNF331 is a transcription factor. FOSB and JUNB are immediate early genes. TRAT1 is in T cells. CD3E is a coreceptor. IFITM1 is interferon-induced. CORO1A is corona protein. COTL1 is collagen-like. JUNB is another immediate early gene. TXNIP is thioredoxin-interacting protein. PTPRC is CD45, a pan-leukocyte marker. NEAT1 is long non-coding RNA. BTG2 is anti-proliferative. GZMM is granzyme M, in cytotoxic cells. PI16 is a kinase. AQP3 is aquaporin 3, maybe endothelial or some neurons. TYMP is thymidine phosphorylase. LSP1 is lysophosphatidylserine-binding protein. TAGAP is transglutaminase. ISG20 is interferon-induced. SAMD3 is involved in apoptosis. CD37 is B-cell marker but also in some T cells. PSAP is pseudoprotein. MYC is oncogene. CD48 is a co-stimulatory molecule. GATA3 is Th2-associated. FBLN5 is fibulins. IFITM2 is interferon-induced. FTH1 is ferritin heavy chain. ZFP36 is involved in mRNA stability. IER2 is stress response. RHOB is GTPase. ARHGDIB is RhoGDI beta. APOBEC3G is antiviral. CD6 is adhesion molecule. THEMIS is interferon-induced. RARRES3 is relaxin. BTG1 is anti-proliferative. NFKBIZ is NF-kappa-B inhibitor. CD53 is pan-leukocyte. EMP3 is extracellular matrix protein. CCND2 is cyclin D2. TUBB is tubulin. RORA is nuclear receptor. LY6E is lymphocyte-specific. PPP1R15A is stress response. GAPDH is housekeeping. LEF1 is transcription factor. HSP90AA1 is heat shock protein. ABI3 is actin binding. H2AFZ is histone. PIK3IP1 is phosphoinositide 3-kinase interacting. MALAT1 is lncRNA. XBP1 is unfolded protein response. GMFG is gelsolin family member. TMSB4X is thymosin beta 4. EVL is ezrin. PRKCH is protein kinase. RPS4Y1 is ribosomal. HSPA8 is heat shock protein. LIMD2 is LIM domain. RGL4 is regulator of G-protein signaling. TC2N is tetracaine-sensitive sodium channel. RCSD1 is calcineurin inhibitor. LCP2 is latrophilin. LDHB is lactate dehydrogenase. SAMHD1 is HIV restriction factor. EVI2A is eukaryotic leucine-rich repeat kinase. CARD16 is caspase recruitment. CISH is cytokine-inducible SH2-containing. HLA-B, -C, -A are MHC class I. LITAF is lipopolysaccharide-induced TNF-alpha factor. FXYD5 is ion channel regulator. RNASET2 is ribonuclease. BEX5 is brain-expressed X-linked. SPN is spondin. HLA-DQB1 is MHC II. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptopic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras guanyl-releasing. MCL1 is anti-apoptotic. BCL2 is anti-apoptotic. ACTG1 is actin. RASGRP2 is Ras guanyl-releasing. HSP90AB1 is heat shock. EMB is embryonal. HLA-DOB is MHC class II. TXN is thioredoxin. NCKAP1L is Nck-associated protein. RASGRP2 is Ras",
         "Naive CD4 T"
        ],
        [
         "33",
         "TTCCAAACCTCCCA",
         " Now let's tackle this problem step by step.\n\nFirstly, the user provided a long list of genes that are said to be highly expressed in a certain type of tumour cell, and wants me to determine the cell type based on these markers. The key is to identify which of these genes are known markers for specific immune or other cell types.\n\nStart with common B-cell markers: CD79A and CD79B (these encode components of the B-cell receptor complex), MS4A1 (CD20, another classic B-cell marker), BANK1, FCRLA, BLK, etc. These suggest that the tumour originates from B-cells.\n\nNext, look at markers associated with germinal centre B-cells. GCB typically expresses genes related to proliferation, survival, and antigen presentation. For example, high expression of HLA class II molecules such as HLA-DRA, HLA-DRB1, HLA-DPA1, HLA-DQB1, HLA-DQA1, HLA-DPB1, etc., indicates active antigen presentation, which is consistent with the function of germinal centre B-cells presenting antigens to T-follicular helper cells.\n\nOther genes like BCL2A1 may be involved in apoptosis regulation, but BCL2 itself is more commonly associated with follicular lymphoma. However, here BCL2A1 might play a role in similar processes. Additionally, genes like LTB (lymphotoxin beta) are important for germinal centre formation and maintenance.\n\nIL7R is usually associated with memory T-cells, but combined with other markers, it may indicate a specific subset. FOS and JUN are early response genes that can be induced during cell activation, supporting an activated state.\n\nLooking at other possible markers: CD38 is often seen in plasma cells and some activated B-cells. CD52 is widely expressed in lymphocytes, including B-cells. CD74 and HLA-DR-related genes reinforce the antigen-presenting cell profile.\n\nNow consider potential confounding factors. For example, some genes like CD37 and CD48 are also found in other B-cell subsets. However, the combination of all these markers points towards a B-cell origin, particularly one that is actively participating in germinal centre reactions—i.e., GCB.\n\nAdditionally, check if there are any markers that might suggest other cell types. For instance, T-cell markers (e.g., CD3, CD8) or myeloid markers (e.g., CD14, CD68) were not prominently featured in the list. This further supports a B-cell derivation.\n\nIn summary, the high expression of B-cell markers (CD79A/B, MS4A1, BANK1, FCRLA, BLK), antigen presentation-related genes (HLA class II family members), and other genes associated with germinal centre functions (LTB, IL7R) strongly suggests that the tumour cells belong to the germinal centre B-cell subtype.</think>Germinal centre B cell",
         "B"
        ],
        [
         "34",
         "TTGAGGACTACGCA",
         " Now let's tackle this long list step by step.\n\nFirst, I'll scan through the gene list for any familiar markers that stand out. Let me start with some key genes mentioned:\n\nMS4A6A: This is part of the MS4A family, which includes CD20 (MS4A1), commonly found in B-cells. But MS4A6A might be specific to other immune cells.\nFCER1G: Found in myeloid cells like mast cells, basophils, dendritic cells.\nLYZ: Lysozyme, often associated with macrophages and monocytes.\nCD74: Involved in antigen presentation, common in antigen-presenting cells like macrophages and dendritic cells.\nHLA-DRA, HLA-DRB1: Part of the MHC class II complex, indicating antigen-presenting cells such as macrophages or dendritic cells.\nTYROBP: Tyrosine kinase binding protein involved in immune receptor signaling, present in various leukocytes including macrophages.\nAIF1 (Allograft inflammatory factor 1): Expressed in macrophages.\nFCER1A: High affinity IgE receptor component, typically in mast cells and NK cells but also in dendritic cells.\nIL1B: Interleukin-1 beta, produced by macrophages during inflammation.\nCD68: Not listed here, but other macrophage markers might be present.\nMS4A6A again appears, along with CD1C, which can be found in dendritic cells.\nSPI1 (PU.1): Key transcription factor for myeloid development, including macrophages and dendritic cells.\nCD3E: Usually part of T-cell receptors, but its presence here could indicate mixed populations or a specific subset.\nCD14 missing, but maybe other markers compensate.\nNow, considering the combination of MHC class II genes (HLA-DRA, etc.), lysosomal enzymes (CTSB, CST3), and immune receptors (FCER1G, FCER1A), this points towards antigen-presenting cells. Macrophages and dendritic cells share many markers. However, the presence of mast cell markers (FCER1A) and basophilic markers (FCER1G) complicates things. Also, CD20 isn't listed, so it's not likely B-cells.\n\nThe key difference between dendritic cells and macrophages lies in their activation states and surface markers. Macrophages might express more M2-related genes, while dendritic cells have different activation stages. Genes like CD1C, CLEC4A (Dectin-1), and CLEC9A (if present) suggest dendritic cells. Additionally, dendritic cells may have higher expression of certain chemokines and co-stimulatory molecules.\n\nAlso, checking for absence of typical macrophage markers like CD163 or CD68 wasn't listed here, though there's AIF1. The presence of FCER1A and FCER1G might lean towards dendritic cells since mast cells usually have more specific markers like KIT (CD117).\n\nPutting this together, despite overlapping markers with macrophages, the combination of FCER1A/G, CLEC family members, and possibly other dendritic-specific genes suggests dendritic cells over macrophages. Therefore, the cell type is most likely conventional dendritic cells.</think>Conventional dendritic cells",
         "DC"
        ]
       ],
       "shape": {
        "columns": 3,
        "rows": 35
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cell_name</th>\n",
       "      <th>response</th>\n",
       "      <th>labels</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ACCGTGCTGGAACG</td>\n",
       "      <td>First, I need to recall what each gene does a...</td>\n",
       "      <td>B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ACGTGATGCCATGA</td>\n",
       "      <td>Now let's tackle this long list of genes.\\n\\n...</td>\n",
       "      <td>DC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>AGCGATTGAGATCC</td>\n",
       "      <td>Now I need to analyze the user-provided gene ...</td>\n",
       "      <td>NK</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>AGCGGGCTTGCCAA</td>\n",
       "      <td>First, I need to identify which of these gene...</td>\n",
       "      <td>Naive CD4 T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>AGGTCTGATTCTCA</td>\n",
       "      <td>Now let's tackle this long list step by step....</td>\n",
       "      <td>FCGR3A+ Mono</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>AGTACTCTCGGTAT</td>\n",
       "      <td>Now let's tackle this long list of genes. The...</td>\n",
       "      <td>Memory CD4 T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>ATACGGACTATGCG</td>\n",
       "      <td>Now let's tackle this problem step by step.\\n...</td>\n",
       "      <td>B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>ATCTTTCTTGTCCC</td>\n",
       "      <td>Now let's tackle this long list of genes. The...</td>\n",
       "      <td>NK</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>CAAAGCACCGTAAC</td>\n",
       "      <td>First, I need to recall what each gene does a...</td>\n",
       "      <td>B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>CCCTAGTGCAAAGA</td>\n",
       "      <td>Now let's tackle this long list of genes.\\n\\n...</td>\n",
       "      <td>Memory CD4 T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>CCTACCGACTCTTA</td>\n",
       "      <td>First, I need to identify which of these gene...</td>\n",
       "      <td>Naive CD4 T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>CGGCGAACTACTTC</td>\n",
       "      <td>Now let's tackle this long list step by step....</td>\n",
       "      <td>NK</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>CGTGTAGAGTTACG</td>\n",
       "      <td>First, I need to recall what each gene does a...</td>\n",
       "      <td>NK</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>CTCCACGAGAGATA</td>\n",
       "      <td>Now let's tackle this long list of genes.\\n\\n...</td>\n",
       "      <td>DC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>CTGAGAACGTAAAG</td>\n",
       "      <td>Now let's tackle this step by step. The user ...</td>\n",
       "      <td>NK</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>GAAAGATGCTGATG</td>\n",
       "      <td>Now let's tackle this long list step by step....</td>\n",
       "      <td>FCGR3A+ Mono</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>GAACCTGAACGTGT</td>\n",
       "      <td>Now let's tackle this long list of genes.\\n\\n...</td>\n",
       "      <td>Memory CD4 T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>GAAGCTACGAATGA</td>\n",
       "      <td>First, I need to identify key markers from th...</td>\n",
       "      <td>CD14+ Mono</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>GAGGTACTACTCAG</td>\n",
       "      <td>Now let's tackle this problem step by step.\\n...</td>\n",
       "      <td>CD14+ Mono</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>GCACGGACCAGCTA</td>\n",
       "      <td>Now let's tackle this long list step by step....</td>\n",
       "      <td>Memory CD4 T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>GCACTAGAAGATGA</td>\n",
       "      <td>Now let's tackle this problem step by step.\\n...</td>\n",
       "      <td>B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>GCCACGGATACTGG</td>\n",
       "      <td>First, I need to recall what each gene does a...</td>\n",
       "      <td>Naive CD4 T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>GCGTAATGCACCAA</td>\n",
       "      <td>Now let's tackle this long list of genes.\\n\\n...</td>\n",
       "      <td>FCGR3A+ Mono</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>GGACCGTGGGAACG</td>\n",
       "      <td>Now let's tackle this long list step by step....</td>\n",
       "      <td>DC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>GGACCTCTGTAAGA</td>\n",
       "      <td>Now let's tackle this long list step by step....</td>\n",
       "      <td>CD14+ Mono</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>GGCCGAACGCAGAG</td>\n",
       "      <td>Now I need to analyze the user-provided gene ...</td>\n",
       "      <td>Naive CD4 T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>GGGAACGAAGCTCA</td>\n",
       "      <td>First, I need to carefully read through the u...</td>\n",
       "      <td>FCGR3A+ Mono</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>GTAGTGTGAGGCGA</td>\n",
       "      <td>Now let's tackle this step by step.\\n\\nFirst,...</td>\n",
       "      <td>CD14+ Mono</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>TATAAGTGACACCA</td>\n",
       "      <td>Now I need to analyze these marker genes step...</td>\n",
       "      <td>FCGR3A+ Mono</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>TGGACCCTACACTG</td>\n",
       "      <td>Now let's tackle this problem step by step.\\n...</td>\n",
       "      <td>CD14+ Mono</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>TTAGTCTGTGCACA</td>\n",
       "      <td>First, I need to identify which of these gene...</td>\n",
       "      <td>Memory CD4 T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>TTATGGCTTATGGC</td>\n",
       "      <td>Now let's tackle this long list of genes.\\n\\n...</td>\n",
       "      <td>DC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>TTCAGACTCTCGAA</td>\n",
       "      <td>First, I need to recall what each gene does a...</td>\n",
       "      <td>Naive CD4 T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>TTCCAAACCTCCCA</td>\n",
       "      <td>Now let's tackle this problem step by step.\\n...</td>\n",
       "      <td>B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>TTGAGGACTACGCA</td>\n",
       "      <td>Now let's tackle this long list step by step....</td>\n",
       "      <td>DC</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         cell_name                                           response  \\\n",
       "0   ACCGTGCTGGAACG   First, I need to recall what each gene does a...   \n",
       "1   ACGTGATGCCATGA   Now let's tackle this long list of genes.\\n\\n...   \n",
       "2   AGCGATTGAGATCC   Now I need to analyze the user-provided gene ...   \n",
       "3   AGCGGGCTTGCCAA   First, I need to identify which of these gene...   \n",
       "4   AGGTCTGATTCTCA   Now let's tackle this long list step by step....   \n",
       "5   AGTACTCTCGGTAT   Now let's tackle this long list of genes. The...   \n",
       "6   ATACGGACTATGCG   Now let's tackle this problem step by step.\\n...   \n",
       "7   ATCTTTCTTGTCCC   Now let's tackle this long list of genes. The...   \n",
       "8   CAAAGCACCGTAAC   First, I need to recall what each gene does a...   \n",
       "9   CCCTAGTGCAAAGA   Now let's tackle this long list of genes.\\n\\n...   \n",
       "10  CCTACCGACTCTTA   First, I need to identify which of these gene...   \n",
       "11  CGGCGAACTACTTC   Now let's tackle this long list step by step....   \n",
       "12  CGTGTAGAGTTACG   First, I need to recall what each gene does a...   \n",
       "13  CTCCACGAGAGATA   Now let's tackle this long list of genes.\\n\\n...   \n",
       "14  CTGAGAACGTAAAG   Now let's tackle this step by step. The user ...   \n",
       "15  GAAAGATGCTGATG   Now let's tackle this long list step by step....   \n",
       "16  GAACCTGAACGTGT   Now let's tackle this long list of genes.\\n\\n...   \n",
       "17  GAAGCTACGAATGA   First, I need to identify key markers from th...   \n",
       "18  GAGGTACTACTCAG   Now let's tackle this problem step by step.\\n...   \n",
       "19  GCACGGACCAGCTA   Now let's tackle this long list step by step....   \n",
       "20  GCACTAGAAGATGA   Now let's tackle this problem step by step.\\n...   \n",
       "21  GCCACGGATACTGG   First, I need to recall what each gene does a...   \n",
       "22  GCGTAATGCACCAA   Now let's tackle this long list of genes.\\n\\n...   \n",
       "23  GGACCGTGGGAACG   Now let's tackle this long list step by step....   \n",
       "24  GGACCTCTGTAAGA   Now let's tackle this long list step by step....   \n",
       "25  GGCCGAACGCAGAG   Now I need to analyze the user-provided gene ...   \n",
       "26  GGGAACGAAGCTCA   First, I need to carefully read through the u...   \n",
       "27  GTAGTGTGAGGCGA   Now let's tackle this step by step.\\n\\nFirst,...   \n",
       "28  TATAAGTGACACCA   Now I need to analyze these marker genes step...   \n",
       "29  TGGACCCTACACTG   Now let's tackle this problem step by step.\\n...   \n",
       "30  TTAGTCTGTGCACA   First, I need to identify which of these gene...   \n",
       "31  TTATGGCTTATGGC   Now let's tackle this long list of genes.\\n\\n...   \n",
       "32  TTCAGACTCTCGAA   First, I need to recall what each gene does a...   \n",
       "33  TTCCAAACCTCCCA   Now let's tackle this problem step by step.\\n...   \n",
       "34  TTGAGGACTACGCA   Now let's tackle this long list step by step....   \n",
       "\n",
       "          labels  \n",
       "0              B  \n",
       "1             DC  \n",
       "2             NK  \n",
       "3    Naive CD4 T  \n",
       "4   FCGR3A+ Mono  \n",
       "5   Memory CD4 T  \n",
       "6              B  \n",
       "7             NK  \n",
       "8              B  \n",
       "9   Memory CD4 T  \n",
       "10   Naive CD4 T  \n",
       "11            NK  \n",
       "12            NK  \n",
       "13            DC  \n",
       "14            NK  \n",
       "15  FCGR3A+ Mono  \n",
       "16  Memory CD4 T  \n",
       "17    CD14+ Mono  \n",
       "18    CD14+ Mono  \n",
       "19  Memory CD4 T  \n",
       "20             B  \n",
       "21   Naive CD4 T  \n",
       "22  FCGR3A+ Mono  \n",
       "23            DC  \n",
       "24    CD14+ Mono  \n",
       "25   Naive CD4 T  \n",
       "26  FCGR3A+ Mono  \n",
       "27    CD14+ Mono  \n",
       "28  FCGR3A+ Mono  \n",
       "29    CD14+ Mono  \n",
       "30  Memory CD4 T  \n",
       "31            DC  \n",
       "32   Naive CD4 T  \n",
       "33             B  \n",
       "34            DC  "
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "output_data_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " First, I need to recall what each gene does and in which cell types they're typically expressed.\n",
      "\n",
      "CD74 and HLA genes (like HLA-DRA, HLA-DRB1) are involved in antigen presentation, so that's a clue for B-cells or other immune cells. MS4A1 is CD20, a classic B-cell marker. CD79A and CD79B are components of the B-cell receptor complex. So this is definitely a B-cell related tumor.\n",
      "\n",
      "Looking at other markers: LTB (lymphotoxin beta), which is involved in lymphoid organ development. BANK1 is associated with B-cell activation. SPIB is a transcription factor important in B-cell differentiation. PTPRC (CD45) is a common leukocyte marker but not specific to B-cells. However, the presence of multiple B-cell markers like CD79A/B, MS4A1, CD19 (though not listed here, maybe other markers compensate), suggests it's a B-cell malignancy.\n",
      "\n",
      "Now, considering different B-cell tumors: Diffuse large B-cell lymphoma (DLBCL) has subtypes, some of which might express these markers. Germinal center B-cell (GCB) vs. activated B-cell (ABC) subtypes have different markers. But without more specific markers, hard to tell. Also, some genes like LMO2 are seen in precursor B-ALL, but that's less likely given the context.\n",
      "\n",
      "The presence of genes like XBP1 might suggest plasma cell differentiation, but that's more common in multiple myeloma. However, if there's a mix, maybe a plasmacytoid dendritic cell? But the combination here seems more B-cell lineage.\n",
      "\n",
      "Other genes like CD3D and CD37 are T-cell markers, but those can sometimes be cross-expressed. However, the strong B-cell markers outweigh that. Maybe a case of mistaken identity?\n",
      "\n",
      "Wait, looking again: The list includes CD52, which is found in various lymphocytes including T and B cells. CD70 is also expressed in activated T and B cells. Some overlap could exist.\n",
      "\n",
      "But the key markers point towards B-cell origin. Given the high expression of multiple HLA class II genes, which are crucial for antigen presentation, along with B-cell receptor components (CD79A/B), surface immunoglobulins (though not listed here), and genes like MS4A1 (CD20), this strongly indicates a B-cell neoplasm.\n",
      "\n",
      "Considering DLBCL as a possibility, but without more specific markers (like CD10 for GCB subtype, or CD23 for ABC), it's hard to specify. Alternatively, chronic lymphocytic leukemia (CLL)? But CLL usually expresses CD5, which isn't mentioned here.\n",
      "\n",
      "Another angle: Some of the genes like IRF8 are involved in B-cell development. SPIB is another transcription factor in B-cells. BANK1 mutations are linked to autoimmune diseases but can be present in B-cell cancers.\n",
      "\n",
      "Given all these B-cell markers and antigen processing genes, the most likely answer is a B-cell lymphoma. Since the question states tumor cells, the cell type would be B-cells. However, the exact subtype isn't specified because of the lack of specific markers. But the primary annotation based on the provided markers is:\n",
      "\n",
      "B cell\n"
     ]
    }
   ],
   "source": [
    "print(output_data_df['response'].iloc[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "deepseek",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
